ID   FGFR1_HUMAN             Reviewed;         822 AA.
AC   P11362; A8K6T9; A8K8V5; C1KBH8; P17049; Q02063; Q02065; Q14306; Q14307;
AC   Q53H63; Q59H40; Q5BJG2; Q8N685; Q9UD50; Q9UDF0; Q9UDF1; Q9UDF2;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1991, sequence version 3.
DT   29-SEP-2021, entry version 267.
DE   RecName: Full=Fibroblast growth factor receptor 1;
DE            Short=FGFR-1;
DE            EC=2.7.10.1 {ECO:0000269|PubMed:1379697, ECO:0000269|PubMed:15117958, ECO:0000269|PubMed:18480409, ECO:0000269|PubMed:19224897, ECO:0000269|PubMed:19665973, ECO:0000269|PubMed:20133753, ECO:0000269|PubMed:8622701};
DE   AltName: Full=Basic fibroblast growth factor receptor 1;
DE            Short=BFGFR;
DE            Short=bFGF-R-1;
DE   AltName: Full=Fms-like tyrosine kinase 2;
DE            Short=FLT-2;
DE   AltName: Full=N-sam;
DE   AltName: Full=Proto-oncogene c-Fgr;
DE   AltName: CD_antigen=CD331;
DE   Flags: Precursor;
GN   Name=FGFR1; Synonyms=BFGFR, CEK, FGFBR, FLG, FLT2, HBGFR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 15).
RC   TISSUE=Placenta;
RX   PubMed=2162671; DOI=10.1016/0006-291x(90)90384-y;
RA   Itoh N., Terachi T., Ohta M., Seo M.K.;
RT   "The complete amino acid sequence of the shorter form of human basic
RT   fibroblast growth factor receptor deduced from its cDNA.";
RL   Biochem. Biophys. Res. Commun. 169:680-685(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INTERACTION WITH FGF1 AND FGF2.
RC   TISSUE=Neonatal brain stem;
RX   PubMed=1697263; DOI=10.1002/j.1460-2075.1990.tb07454.x;
RA   Dionne C.A., Crumley G.R., Bellot F., Kaplow J.M., Searfoss G., Ruta M.,
RA   Burgess W.H., Jaye M., Schlessinger J.;
RT   "Cloning and expression of two distinct high-affinity receptors cross-
RT   reacting with acidic and basic fibroblast growth factors.";
RL   EMBO J. 9:2685-2692(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 6; 15; 17 AND 18).
RX   PubMed=2167437; DOI=10.1128/mcb.10.9.4728-4736.1990;
RA   Johnson D.E., Lee P.L., Lu J., Williams L.T.;
RT   "Diverse forms of a receptor for acidic and basic fibroblast growth
RT   factors.";
RL   Mol. Cell. Biol. 10:4728-4736(1990).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=2159626; DOI=10.1093/nar/18.7.1906;
RA   Isacchi A., Bergonzoni L., Sarmientos P.;
RT   "Complete sequence of a human receptor for acidic and basic fibroblast
RT   growth factors.";
RL   Nucleic Acids Res. 18:1906-1906(1990).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 14), AND INTERACTION WITH FGF1 AND
RP   FGF2.
RC   TISSUE=Teratocarcinoma;
RX   PubMed=1722683; DOI=10.3109/08977199109104816;
RA   Wennstroem S., Sandstroem C., Claesson-Welsh L.;
RT   "cDNA cloning and expression of a human FGF receptor which binds acidic and
RT   basic FGF.";
RL   Growth Factors 4:197-208(1991).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 14).
RX   PubMed=1662973; DOI=10.3109/08977199109000276;
RA   Kiefer M.C., Baird A., George-Nascimento C., Nguyen T., Mason O.B.,
RA   Boley L.J., Valenzuela P., Barr P.J.;
RT   "Molecular cloning of a human basic fibroblast growth factor receptor cDNA
RT   and expression of a biologically active extracellular domain in a
RT   baculovirus system.";
RL   Growth Factors 5:115-127(1991).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 6; 14; 15 AND 16).
RC   TISSUE=Lung;
RX   PubMed=1650441;
RA   Eisemann A., Ahn J.A., Graziani G., Tronick S.R., Ron D.;
RT   "Alternative splicing generates at least five different isoforms of the
RT   human basic-FGF receptor.";
RL   Oncogene 6:1195-1202(1991).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3; 4; 5; 6; 7; 8; 9; 10; 11; 12
RP   AND 13).
RC   TISSUE=Liver;
RX   PubMed=1846977; DOI=10.1126/science.1846977;
RA   Hou J., Kan M., McKeehan K., McBride G., Adams P., McKeehan W.L.;
RT   "Fibroblast growth factor receptors from liver vary in three structural
RT   domains.";
RL   Science 251:665-668(1991).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1317750;
RA   Hattori Y., Odagiri H., Katoh O., Sakamoto H., Morita T., Shimotohno K.,
RA   Tobinai K., Sugimura T., Terada M.;
RT   "K-sam-related gene, N-sam, encodes fibroblast growth factor receptor and
RT   is expressed in T-lymphocytic tumors.";
RL   Cancer Res. 52:3367-3371(1992).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 19), AND ROLE IN DISEASE.
RX   PubMed=20139426; DOI=10.1093/humrep/deq006;
RA   Miura K., Miura S., Yoshiura K., Seminara S., Hamaguchi D., Niikawa N.,
RA   Masuzaki H.;
RT   "A case of Kallmann syndrome carrying a missense mutation in alternatively
RT   spliced exon 8A encoding the immunoglobulin-like domain IIIb of fibroblast
RT   growth factor receptor 1.";
RL   Hum. Reprod. 25:1076-1080(2010).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 6; 14 AND 21).
RC   TISSUE=Placenta, and Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 14 AND 20).
RC   TISSUE=Brain, and Colon;
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-22; ARG-818 AND
RP   CYS-822.
RG   NIEHS SNPs program;
RL   Submitted (MAR-2004) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16421571; DOI=10.1038/nature04406;
RA   Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S., Garber M.,
RA   Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A., Chang J.L.,
RA   Cuomo C.A., Dewar K., FitzGerald M.G., Yang X., Allen N.R., Anderson S.,
RA   Asakawa T., Blechschmidt K., Bloom T., Borowsky M.L., Butler J., Cook A.,
RA   Corum B., DeArellano K., DeCaprio D., Dooley K.T., Dorris L. III,
RA   Engels R., Gloeckner G., Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K.,
RA   Jaffe D.B., Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P.,
RA   Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H.,
RA   Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C., O'Leary S.B.,
RA   O'Neill K., Parker S.C.J., Polley A., Raymond C.K., Reichwald K.,
RA   Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R., Smith C.L.,
RA   Sneddon T.P., Talamas J.A., Tenzin P., Topham K., Venkataraman V., Wen G.,
RA   Yamazaki S., Young S.K., Zeng Q., Zimmer A.R., Rosenthal A., Birren B.W.,
RA   Platzer M., Shimizu N., Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 8.";
RL   Nature 439:331-335(2006).
RN   [15]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 4; 14 AND 15), AND VARIANT
RP   GLY-213.
RC   TISSUE=Pancreas, Testis, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [16]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-370 (ISOFORM 15), AND PROTEIN SEQUENCE OF
RP   22-129 (ISOFORM 15).
RX   PubMed=7520751; DOI=10.1021/bi00200a003;
RA   Pantoliano M.W., Horlick R.A., Springer B.A., Van Dyk D.E., Tobery T.,
RA   Wetmore D.R., Lear J.D., Nahapetian A.T., Bradley J.D., Sisk W.P.;
RT   "Multivalent ligand-receptor binding interactions in the fibroblast growth
RT   factor system produce a cooperative growth factor and heparin mechanism for
RT   receptor dimerization.";
RL   Biochemistry 33:10229-10248(1994).
RN   [17]
RP   PROTEIN SEQUENCE OF 81-100 (ISOFORMS 1/2/4/5/14/16).
RX   PubMed=8074689; DOI=10.1006/bbrc.1994.2203;
RA   Rusnati M., Coltrini D., Caccia P., Dell'Era P., Zoppetti G., Oreste P.,
RA   Valsasina B., Presta M.;
RT   "Distinct role of 2-O-, N-, and 6-O-sulfate groups of heparin in the
RT   formation of the ternary complex with basic fibroblast growth factor and
RT   soluble FGF receptor-1.";
RL   Biochem. Biophys. Res. Commun. 203:450-458(1994).
RN   [18]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 201-822 (ISOFORMS 1/6/10/14/15).
RA   Ruta M., Howk R., Ricca G., Drohan W., Zabelshansky M., Laureys G.,
RA   Barton D.E., Francke U., Schlessinger J., Givol D.;
RT   "A novel protein tyrosine kinase gene whose expression is modulated during
RT   endothelial cell differentiation.";
RL   Oncogene 3:9-15(1988).
RN   [19]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 313-391 (ISOFORMS 17/18), NUCLEOTIDE
RP   SEQUENCE [GENOMIC DNA] OF 313-360 (ISOFORMS
RP   1/2/4/5/6/7/8/9/10/11/12/13/14/15), NUCLEOTIDE SEQUENCE [GENOMIC DNA /
RP   MRNA] OF 313-360 (ISOFORM 19), AND TISSUE SPECIFICITY.
RC   TISSUE=Foreskin fibroblast, and Umbilical vein;
RX   PubMed=1652059; DOI=10.1128/mcb.11.9.4627-4634.1991;
RA   Johnson D.E., Lu J., Chen H., Werner S., Williams L.T.;
RT   "The human fibroblast growth factor receptor genes: a common structural
RT   arrangement underlies the mechanisms for generating receptor forms that
RT   differ in their third immunoglobulin domain.";
RL   Mol. Cell. Biol. 11:4627-4634(1991).
RN   [20]
RP   PARTIAL NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=1847500; DOI=10.1128/mcb.11.3.1500-1507.1991;
RA   Gutkind S.J., Link D.C., Katamine S., Lacal P., Miki T., Ley T.J.,
RA   Robbins K.C.;
RT   "A novel c-fgr exon utilized in Epstein-Barr virus-infected B lymphocytes
RT   but not in normal monocytes.";
RL   Mol. Cell. Biol. 11:1500-1507(1991).
RN   [21]
RP   INTERACTION WITH PLCG1.
RX   PubMed=1656221; DOI=10.1128/mcb.11.10.5068-5078.1991;
RA   Mohammadi M., Honegger A.M., Rotin D., Fischer R., Bellot F., Li W.,
RA   Dionne C.A., Jaye M., Rubinstein M., Schlessinger J.;
RT   "A tyrosine-phosphorylated carboxy-terminal peptide of the fibroblast
RT   growth factor receptor (Flg) is a binding site for the SH2 domain of
RT   phospholipase C-gamma 1.";
RL   Mol. Cell. Biol. 11:5068-5078(1991).
RN   [22]
RP   MUTAGENESIS OF TYR-766, FUNCTION, CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION,
RP   AND INTERACTION WITH PLCG1.
RX   PubMed=1379697; DOI=10.1038/358678a0;
RA   Peters K.G., Marie J., Wilson E., Ives H.E., Escobedo J., del Rosario M.,
RA   Mirda D., Williams L.T.;
RT   "Point mutation of an FGF receptor abolishes phosphatidylinositol turnover
RT   and Ca2+ flux but not mitogenesis.";
RL   Nature 358:678-681(1992).
RN   [23]
RP   MUTAGENESIS OF TYR-766, AND FUNCTION IN CELL PROLIFERATION.
RX   PubMed=1379698; DOI=10.1038/358681a0;
RA   Mohammadi M., Dionne C.A., Li W., Lin N., Spivak T., Honegger A.M.,
RA   Jaye M., Schlessinger J.;
RT   "Point mutation in FGF receptor eliminates phosphatidylinositol hydrolysis
RT   without affecting mitogenesis.";
RL   Nature 358:681-684(1992).
RN   [24]
RP   MUTAGENESIS OF TYR-766, AND SUBCELLULAR LOCATION.
RX   PubMed=7516330;
RA   Sorokin A., Mohammadi M., Huang J., Schlessinger J.;
RT   "Internalization of fibroblast growth factor receptor is inhibited by a
RT   point mutation at tyrosine 766.";
RL   J. Biol. Chem. 269:17056-17061(1994).
RN   [25]
RP   PHOSPHORYLATION AT TYR-463; TYR-583; TYR-585; TYR-653; TYR-654 AND TYR-730,
RP   CATALYTIC ACTIVITY, ACTIVITY REGULATION, FUNCTION IN PHOSPHORYLATION OF
RP   PLCG1 AND SHC1; ACTIVATION OF MAP KINASES AND REGULATION OF CELL
RP   PROLIFERATION AND DIFFERENTIATION, AND MUTAGENESIS OF TYR-653 AND TYR-654.
RX   PubMed=8622701; DOI=10.1128/mcb.16.3.977;
RA   Mohammadi M., Dikic I., Sorokin A., Burgess W.H., Jaye M., Schlessinger J.;
RT   "Identification of six novel autophosphorylation sites on fibroblast growth
RT   factor receptor 1 and elucidation of their importance in receptor
RT   activation and signal transduction.";
RL   Mol. Cell. Biol. 16:977-989(1996).
RN   [26]
RP   INTERACTION WITH FGF1; FGF2; FGF4; FGF5; FGF6, AND FUNCTION IN CELL
RP   PROLIFERATION.
RX   PubMed=8663044; DOI=10.1074/jbc.271.25.15292;
RA   Ornitz D.M., Xu J., Colvin J.S., McEwen D.G., MacArthur C.A., Coulier F.,
RA   Gao G., Goldfarb M.;
RT   "Receptor specificity of the fibroblast growth factor family.";
RL   J. Biol. Chem. 271:15292-15297(1996).
RN   [27]
RP   CHROMOSOMAL TRANSLOCATION WITH ZMYM2.
RX   PubMed=9716603;
RA   Reiter A., Sohal J., Kulkarni S., Chase A., Macdonald D.H.C.,
RA   Aguiar R.C.T., Goncalves C., Hernandez J.M., Jennings B.A., Goldman J.M.,
RA   Cross N.C.P.;
RT   "Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in
RT   the t(8;13)(p11;q12) myeloproliferative syndrome.";
RL   Blood 92:1735-1742(1998).
RN   [28]
RP   INTERACTION WITH FGF1, AND PHOSPHORYLATION.
RX   PubMed=9655399; DOI=10.1038/31741;
RA   DiGabriele A.D., Lax I., Chen D.I., Svahn C.M., Jaye M., Schlessinger J.,
RA   Hendrickson W.A.;
RT   "Structure of a heparin-linked biologically active dimer of fibroblast
RT   growth factor.";
RL   Nature 393:812-817(1998).
RN   [29]
RP   CHROMOSOMAL TRANSLOCATION WITH CEP43.
RX   PubMed=9949182;
RA   Popovici C., Zhang B., Gregoire M.-J., Jonveaux P., Lafage-Pochitaloff M.,
RA   Birnbaum D., Pebusque M.-J.;
RT   "The t(6;8)(q27;p11) translocation in a stem cell myeloproliferative
RT   disorder fuses a novel gene, FOP, to fibroblast growth factor receptor 1.";
RL   Blood 93:1381-1389(1999).
RN   [30]
RP   INTERACTION WITH GRB10.
RX   PubMed=10454568; DOI=10.1128/mcb.19.9.6217;
RA   Wang J., Dai H., Yousaf N., Moussaif M., Deng Y., Boufelliga A.,
RA   Swamy O.R., Leone M.E., Riedel H.;
RT   "Grb10, a positive, stimulatory signaling adapter in platelet-derived
RT   growth factor BB-, insulin-like growth factor I-, and insulin-mediated
RT   mitogenesis.";
RL   Mol. Cell. Biol. 19:6217-6228(1999).
RN   [31]
RP   INVOLVEMENT IN JWS, AND VARIANT JWS ARG-252.
RX   PubMed=10861678;
RX   DOI=10.1002/1096-8628(20000703)93:1<22::aid-ajmg5>3.0.co;2-u;
RA   Roscioli T., Flanagan S., Kumar P., Masel J., Gattas M., Hyland V.J.,
RA   Glass I.A.;
RT   "Clinical findings in a patient with FGFR1 P252R mutation and comparison
RT   with the literature.";
RL   Am. J. Med. Genet. 93:22-28(2000).
RN   [32]
RP   CHROMOSOMAL TRANSLOCATION WITH CNTRL.
RX   PubMed=10688839;
RA   Guasch G., Mack G.J., Popovici C., Dastugue N., Birnbaum D., Rattner J.B.,
RA   Pebusque M.-J.;
RT   "FGFR1 is fused to the centrosome-associated protein CEP110 in the 8p12
RT   stem cell myeloproliferative disorder with t(8;9)(p12;q33).";
RL   Blood 95:1788-1796(2000).
RN   [33]
RP   FUNCTION IN PHOSPHORYLATION OF FRS2 AND GAB1 AND IN ACTIVATION OF PIK3R1.
RX   PubMed=11353842; DOI=10.1073/pnas.111114298;
RA   Ong S.H., Hadari Y.R., Gotoh N., Guy G.R., Schlessinger J., Lax I.;
RT   "Stimulation of phosphatidylinositol 3-kinase by fibroblast growth factor
RT   receptors is mediated by coordinated recruitment of multiple docking
RT   proteins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:6074-6079(2001).
RN   [34]
RP   FUNCTION IN ACTIVATION OF SIGNALING VIA RAS AND MAP KINASES AND CELL
RP   PROLIFERATION, FUNCTION IN PHOSPHORYLATION OF FRS2; SHB AND PTPN11/SHP2,
RP   INTERACTION WITH SHB AND FGF2, AND MUTAGENESIS OF TYR-766.
RX   PubMed=12181353; DOI=10.1091/mbc.e02-02-0103;
RA   Cross M.J., Lu L., Magnusson P., Nyqvist D., Holmqvist K., Welsh M.,
RA   Claesson-Welsh L.;
RT   "The Shb adaptor protein binds to tyrosine 766 in the FGFR-1 and regulates
RT   the Ras/MEK/MAPK pathway via FRS2 phosphorylation in endothelial cells.";
RL   Mol. Biol. Cell 13:2881-2893(2002).
RN   [35]
RP   CHROMOSOMAL TRANSLOCATION WITH FGFR1OP2.
RX   PubMed=15034873; DOI=10.1002/gcc.20023;
RA   Grand E.K., Grand F.H., Chase A.J., Ross F.M., Corcoran M.M., Oscier D.G.,
RA   Cross N.C.P.;
RT   "Identification of a novel gene, FGFR1OP2, fused to FGFR1 in 8p11
RT   myeloproliferative syndrome.";
RL   Genes Chromosomes Cancer 40:78-83(2004).
RN   [36]
RP   FUNCTION IN ACTIVATION OF RPS6KA1 AND CREB1, CATALYTIC ACTIVITY,
RP   INTERACTION WITH RPS6KA1, MUTAGENESIS OF LYS-514, AND SUBCELLULAR LOCATION.
RX   PubMed=15117958; DOI=10.1074/jbc.m311144200;
RA   Hu Y., Fang X., Dunham S.M., Prada C., Stachowiak E.K., Stachowiak M.K.;
RT   "90-kDa ribosomal S6 kinase is a direct target for the nuclear fibroblast
RT   growth factor receptor 1 (FGFR1): role in FGFR1 signaling.";
RL   J. Biol. Chem. 279:29325-29335(2004).
RN   [37]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-296.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E., Moore R.J.,
RA   Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [38]
RP   CHROMOSOMAL TRANSLOCATION WITH FGFR1OP2.
RX   PubMed=16946300; DOI=10.1182/blood-2006-06-026666;
RA   Gu T.-L., Goss V.L., Reeves C., Popova L., Nardone J., Macneill J.,
RA   Walters D.K., Wang Y., Rush J., Comb M.J., Druker B.J., Polakiewicz R.D.;
RT   "Phosphotyrosine profiling identifies the KG-1 cell line as a model for the
RT   study of FGFR1 fusions in acute myeloid leukemia.";
RL   Blood 108:4202-4204(2006).
RN   [39]
RP   INTERACTION WITH FGF1; FGF8; FGF10; FGF19; FGF21; FGF22 AND FGF23, AND
RP   FUNCTION IN STIMULATION OF CELL PROLIFERATION.
RX   PubMed=16597617; DOI=10.1074/jbc.m601252200;
RA   Zhang X., Ibrahimi O.A., Olsen S.K., Umemori H., Mohammadi M., Ornitz D.M.;
RT   "Receptor specificity of the fibroblast growth factor family. The complete
RT   mammalian FGF family.";
RL   J. Biol. Chem. 281:15694-15700(2006).
RN   [40]
RP   SUBCELLULAR LOCATION, AND GLYCOSYLATION.
RX   PubMed=16481405; DOI=10.1091/mbc.e05-08-0749;
RA   Dunham-Ems S.M., Pudavar H.E., Myers J.M., Maher P.A., Prasad P.N.,
RA   Stachowiak M.K.;
RT   "Factors controlling fibroblast growth factor receptor-1's cytoplasmic
RT   trafficking and its regulation as revealed by FRAP analysis.";
RL   Mol. Biol. Cell 17:2223-2235(2006).
RN   [41]
RP   PHOSPHORYLATION AT TYR-463; TYR-653; TYR-654; TYR-583 AND TYR-585, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=16507368; DOI=10.1016/j.molcel.2006.01.022;
RA   Furdui C.M., Lew E.D., Schlessinger J., Anderson K.S.;
RT   "Autophosphorylation of FGFR1 kinase is mediated by a sequential and
RT   precisely ordered reaction.";
RL   Mol. Cell 21:711-717(2006).
RN   [42]
RP   CHROMOSOMAL TRANSLOCATION WITH FGFR1OP2.
RX   PubMed=17389761; DOI=10.1182/blood-2006-12-065615;
RA   Dong S., Kang S., Gu T., Kardar S., Fu H., Lonial S., Khoury H.J.,
RA   Khuri F., Chen J.;
RT   "14-3-3 integrates pro-survival signals mediated by the AKT and MAPK
RT   pathways in ZNF198-FGFR1 transformed hematopoietic cells.";
RL   Blood 110:360-369(2007).
RN   [43]
RP   INTERACTION WITH FGF19; FGF21 AND KLB, AND FUNCTION IN REGULATION OF
RP   GLUCOSE UPTAKE IN ADIPOCYTES.
RX   PubMed=17623664; DOI=10.1074/jbc.m704165200;
RA   Kurosu H., Choi M., Ogawa Y., Dickson A.S., Goetz R., Eliseenkova A.V.,
RA   Mohammadi M., Rosenblatt K.P., Kliewer S.A., Kuro-o M.;
RT   "Tissue-specific expression of betaKlotho and fibroblast growth factor
RT   (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21.";
RL   J. Biol. Chem. 282:26687-26695(2007).
RN   [44]
RP   FUNCTION IN STAT1 PHOSPHORYLATION, GLYCOSYLATION, AND PHOSPHORYLATION.
RX   PubMed=17311277; DOI=10.1002/jcp.21014;
RA   Citores L., Bai L., Sorensen V., Olsnes S.;
RT   "Fibroblast growth factor receptor-induced phosphorylation of STAT1 at the
RT   Golgi apparatus without translocation to the nucleus.";
RL   J. Cell. Physiol. 212:148-156(2007).
RN   [45]
RP   BINDING TO FGF1, AND IDENTIFICATION IN A COMPLEX WITH INTEGRIN AND FGF1.
RX   PubMed=18441324; DOI=10.1074/jbc.m801213200;
RA   Mori S., Wu C.Y., Yamaji S., Saegusa J., Shi B., Ma Z., Kuwabara Y.,
RA   Lam K.S., Isseroff R.R., Takada Y.K., Takada Y.;
RT   "Direct binding of integrin alphavbeta3 to FGF1 plays a role in FGF1
RT   signaling.";
RL   J. Biol. Chem. 283:18066-18075(2008).
RN   [46]
RP   UBIQUITINATION, CATALYTIC ACTIVITY, FUNCTION AS FGF1 RECEPTOR AND IN
RP   ACTIVATION OF PLCG1; FRS2; MAPK1/ERK2 AND MAPK3/ERK1, ACTIVITY REGULATION,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=18480409; DOI=10.1091/mbc.e07-12-1219;
RA   Haugsten E.M., Malecki J., Bjorklund S.M., Olsnes S., Wesche J.;
RT   "Ubiquitination of fibroblast growth factor receptor 1 is required for its
RT   intracellular sorting but not for its endocytosis.";
RL   Mol. Biol. Cell 19:3390-3403(2008).
RN   [47]
RP   INTERACTION WITH ANOS1.
RX   PubMed=19696444; DOI=10.1074/jbc.m109.049155;
RA   Hu Y., Guimond S.E., Travers P., Cadman S., Hohenester E., Turnbull J.E.,
RA   Kim S.H., Bouloux P.M.;
RT   "Novel mechanisms of fibroblast growth factor receptor 1 regulation by
RT   extracellular matrix protein anosmin-1.";
RL   J. Biol. Chem. 284:29905-29920(2009).
RN   [48]
RP   FUNCTION IN CHROMATIN BINDING AND TRANSCRIPTION REGULATION, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=19261810; DOI=10.1091/mbc.e08-06-0600;
RA   Dunham-Ems S.M., Lee Y.W., Stachowiak E.K., Pudavar H., Claus P.,
RA   Prasad P.N., Stachowiak M.K.;
RT   "Fibroblast growth factor receptor-1 (FGFR1) nuclear dynamics reveal a
RT   novel mechanism in transcription control.";
RL   Mol. Biol. Cell 20:2401-2412(2009).
RN   [49]
RP   FUNCTION AS PROTO-ONCOGENE, ACTIVE SITE, MUTAGENESIS OF ASP-623, CATALYTIC
RP   ACTIVITY, PHOSPHORYLATION AT TYR-463; TYR-653; TYR-654; TYR-583; TYR-585
RP   AND TYR-730, CHARACTERIZATION OF VARIANT ECCL LYS-546, IDENTIFICATION BY
RP   MASS SPECTROMETRY, AND ACTIVITY REGULATION.
RX   PubMed=19224897; DOI=10.1126/scisignal.2000021;
RA   Lew E.D., Furdui C.M., Anderson K.S., Schlessinger J.;
RT   "The precise sequence of FGF receptor autophosphorylation is kinetically
RT   driven and is disrupted by oncogenic mutations.";
RL   Sci. Signal. 2:RA6-RA6(2009).
RN   [50]
RP   BINDING TO FGF1, AND IDENTIFICATION IN A COMPLEX WITH INTEGRIN AND FGF1.
RX   PubMed=20422052; DOI=10.1371/journal.pone.0010273;
RA   Yamaji S., Saegusa J., Ieguchi K., Fujita M., Mori S., Takada Y.K.,
RA   Takada Y.;
RT   "A novel fibroblast growth factor-1 (FGF1) mutant that acts as an FGF
RT   antagonist.";
RL   PLoS ONE 5:E10273-E10273(2010).
RN   [51]
RP   INTERACTION WITH FGF23 AND KLB.
RX   PubMed=19966287; DOI=10.1073/pnas.0902006107;
RA   Goetz R., Nakada Y., Hu M.C., Kurosu H., Wang L., Nakatani T., Shi M.,
RA   Eliseenkova A.V., Razzaque M.S., Moe O.W., Kuro-o M., Mohammadi M.;
RT   "Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by
RT   inhibiting FGF23-FGFR-Klotho complex formation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:407-412(2010).
RN   [52]
RP   FUNCTION IN ACTIVATION OF AKT1; PLCG1; MAPK1/ERK2, MAPK3/ERK1 AND MAP
RP   KINASE SIGNALING, FUNCTION IN REGULATION OF NEURONAL DIFFERENTIATION AND
RP   EMBRYONIC DEVELOPMENT, SUBCELLULAR LOCATION, INTERACTION WITH NEDD4; PLCG1
RP   AND FRS2, UBIQUITINATION, AND DEGRADATION.
RX   PubMed=21765395; DOI=10.1038/emboj.2011.234;
RA   Persaud A., Alberts P., Hayes M., Guettler S., Clarke I., Sicheri F.,
RA   Dirks P., Ciruna B., Rotin D.;
RT   "Nedd4-1 binds and ubiquitylates activated FGFR1 to control its endocytosis
RT   and function.";
RL   EMBO J. 30:3259-3273(2011).
RN   [53]
RP   REVIEW ON ALTERNATIVE SPLICE FORMS; LIGANDS; SIGNALING PATHWAYS AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=12141425;
RA   Groth C., Lardelli M.;
RT   "The structure and function of vertebrate fibroblast growth factor receptor
RT   1.";
RL   Int. J. Dev. Biol. 46:393-400(2002).
RN   [54]
RP   REVIEW ON FUNCTION; ROLE IN DISEASE; SIGNALING PATHWAYS; SUBUNIT; DOMAIN
RP   STRUCTURE; LIGAND SELECTIVITY AND ACTIVITY REGULATION.
RX   PubMed=15863030; DOI=10.1016/j.cytogfr.2005.01.001;
RA   Eswarakumar V.P., Lax I., Schlessinger J.;
RT   "Cellular signaling by fibroblast growth factor receptors.";
RL   Cytokine Growth Factor Rev. 16:139-149(2005).
RN   [55]
RP   REVIEW ON FUNCTION IN FGF SIGNALING.
RX   PubMed=20094046; DOI=10.1038/nrc2780;
RA   Turner N., Grose R.;
RT   "Fibroblast growth factor signalling: from development to cancer.";
RL   Nat. Rev. Cancer 10:116-129(2010).
RN   [56]
RP   REVIEW ON SIGNALING AND ROLE IN KALLMAN SYNDROME.
RX   PubMed=20117945; DOI=10.1016/j.tem.2010.01.004;
RA   Hu Y., Bouloux P.M.;
RT   "Novel insights in FGFR1 regulation: lessons from Kallmann syndrome.";
RL   Trends Endocrinol. Metab. 21:385-393(2010).
RN   [57]
RP   INVOLVEMENT IN ECCL, VARIANTS ECCL LYS-546 AND GLU-656, AND VARIANT
RP   MET-561.
RX   PubMed=26942290; DOI=10.1016/j.ajhg.2016.02.006;
RG   University of Washington Center for Mendelian Genomics;
RG   Care4Rare Canada Consortium;
RA   Bennett J.T., Tan T.Y., Alcantara D., Tetrault M., Timms A.E., Jensen D.,
RA   Collins S., Nowaczyk M.J., Lindhurst M.J., Christensen K.M., Braddock S.R.,
RA   Brandling-Bennett H., Hennekam R.C., Chung B., Lehman A., Su J., Ng S.,
RA   Amor D.J., Majewski J., Biesecker L.G., Boycott K.M., Dobyns W.B.,
RA   O'Driscoll M., Moog U., McDonell L.M.;
RT   "Mosaic activating mutations in FGFR1 cause encephalocraniocutaneous
RT   lipomatosis.";
RL   Am. J. Hum. Genet. 98:579-587(2016).
RN   [58]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 464-762.
RX   PubMed=8752212; DOI=10.1016/s0092-8674(00)80131-2;
RA   Mohammadi M., Schlessinger J., Hubbard S.R.;
RT   "Structure of the FGF receptor tyrosine kinase domain reveals a novel
RT   autoinhibitory mechanism.";
RL   Cell 86:577-587(1996).
RN   [59]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 464-762 IN COMPLEX WITH SU4984.
RX   PubMed=9139660; DOI=10.1126/science.276.5314.955;
RA   Mohammadi M., McMahon G., Sun L., Tang C., Hirth P., Yeh B.K.,
RA   Hubbard S.R., Schlessinger J.;
RT   "Structures of the tyrosine kinase domain of fibroblast growth factor
RT   receptor in complex with inhibitors.";
RL   Science 276:955-960(1997).
RN   [60]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 141-365 IN COMPLEX WITH FGF1,
RP   FUNCTION, AND DISULFIDE BONDS.
RX   PubMed=10830168; DOI=10.1016/s0092-8674(00)80851-x;
RA   Plotnikov A.N., Hubbard S.R., Schlessinger J., Mohammadi M.;
RT   "Crystal structures of two FGF-FGFR complexes reveal the determinants of
RT   ligand-receptor specificity.";
RL   Cell 101:413-424(2000).
RN   [61]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 143-364 IN COMPLEX WITH FGF2 AND
RP   HEPARIN, AND DISULFIDE BONDS.
RX   PubMed=11030354; DOI=10.1016/s1097-2765(00)00073-3;
RA   Schlessinger J., Plotnikov A.N., Ibrahimi O.A., Eliseenkova A.V., Yeh B.K.,
RA   Yayon A., Linhardt R.J., Mohammadi M.;
RT   "Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual
RT   role for heparin in FGFR binding and dimerization.";
RL   Mol. Cell 6:743-750(2000).
RN   [62]
RP   STRUCTURE BY NMR OF 38-124.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the first Ig-like domain of human fibroblast growth
RT   factor receptor 1.";
RL   Submitted (NOV-2005) to the PDB data bank.
RN   [63]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 458-774 IN COMPLEX WITH PLCG1 AND
RP   ATP ANALOG, FUNCTION, CATALYTIC ACTIVITY, SUBUNIT, AUTOPHOSPHORYLATION, AND
RP   PHOSPHORYLATION AT TYR-653; TYR-654 AND TYR-766.
RX   PubMed=19665973; DOI=10.1016/j.cell.2009.05.028;
RA   Bae J.H., Lew E.D., Yuzawa S., Tome F., Lax I., Schlessinger J.;
RT   "The selectivity of receptor tyrosine kinase signaling is controlled by a
RT   secondary SH2 domain binding site.";
RL   Cell 138:514-524(2009).
RN   [64]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 458-765 OF MUTANT GLU-577,
RP   FUNCTION, CATALYTIC ACTIVITY, SUBUNIT, AND MUTAGENESIS OF ARG-577.
RX   PubMed=20133753; DOI=10.1073/pnas.0914157107;
RA   Bae J.H., Boggon T.J., Tome F., Mandiyan V., Lax I., Schlessinger J.;
RT   "Asymmetric receptor contact is required for tyrosine autophosphorylation
RT   of fibroblast growth factor receptor in living cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:2866-2871(2010).
RN   [65]
RP   X-RAY CRYSTALLOGRAPHY (2.01 ANGSTROMS) OF 461-765 IN COMPLEX WITH ARQ 069,
RP   AND ACTIVITY REGULATION.
RX   PubMed=21454610; DOI=10.1074/jbc.m110.213736;
RA   Eathiraj S., Palma R., Hirschi M., Volckova E., Nakuci E., Castro J.,
RA   Chen C.R., Chan T.C., France D.S., Ashwell M.A.;
RT   "A novel mode of protein kinase inhibition exploiting hydrophobic motifs of
RT   autoinhibited kinases: discovery of ATP-independent inhibitors of
RT   fibroblast growth factor receptor.";
RL   J. Biol. Chem. 286:20677-20687(2011).
RN   [66]
RP   VARIANT PS ARG-252.
RX   PubMed=7874169; DOI=10.1038/ng1194-269;
RA   Muenke M., Schell U., Hehr A., Robin N.H., Losken H.W., Schinzel A.,
RA   Pulleyn L.J., Rutland P., Reardon W., Malcolm S., Winter R.M.;
RT   "A common mutation in the fibroblast growth factor receptor 1 gene in
RT   Pfeiffer syndrome.";
RL   Nat. Genet. 8:269-274(1994).
RN   [67]
RP   VARIANT TRIGNO1 THR-300.
RX   PubMed=11173846; DOI=10.1159/000056834;
RA   Kress W., Petersen B., Collmann H., Grimm T.;
RT   "An unusual FGFR1 mutation (fibroblast growth factor receptor 1 mutation)
RT   in a girl with non-syndromic trigonocephaly.";
RL   Cytogenet. Cell Genet. 91:138-140(2000).
RN   [68]
RP   VARIANTS HH2 ASP-97; CYS-99; SER-167; TYR-277; MET-607; 622-ARG--ARG-822
RP   DEL; ARG-666 AND ARG-719, AND VARIANT SER-772.
RX   PubMed=12627230; DOI=10.1038/ng1122;
RA   Dode C., Levilliers J., Dupont J.-M., De Paepe A., Le Du N.,
RA   Soussi-Yanicostas N., Coimbra R.S., Delmaghani S., Compain-Nouaille S.,
RA   Baverel F., Pecheux C., Le Tessier D., Cruaud C., Delpech M., Speleman F.,
RA   Vermeulen S., Amalfitano A., Bachelot Y., Bouchard P., Cabrol S.,
RA   Carel J.-C., Delemarre-van de Waal H., Goulet-Salmon B., Kottler M.-L.,
RA   Richard O., Sanchez-Franco F., Saura R., Young J., Petit C.,
RA   Hardelin J.-P.;
RT   "Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann
RT   syndrome.";
RL   Nat. Genet. 33:463-465(2003).
RN   [69]
RP   VARIANT HH2 SER-745.
RX   PubMed=15001591; DOI=10.1210/jc.2003-030476;
RA   Sato N., Katsumata N., Kagami M., Hasegawa T., Hori N., Kawakita S.,
RA   Minowada S., Shimotsuka A., Shishiba Y., Yokozawa M., Yasuda T.,
RA   Nagasaki K., Hasegawa D., Hasegawa Y., Tachibana K., Naiki Y., Horikawa R.,
RA   Tanaka T., Ogata T.;
RT   "Clinical assessment and mutation analysis of Kallmann syndrome 1 (KAL1)
RT   and fibroblast growth factor receptor 1 (FGFR1, or KAL2) in five families
RT   and 18 sporadic patients.";
RL   J. Clin. Endocrinol. Metab. 89:1079-1088(2004).
RN   [70]
RP   VARIANTS OGD ILE-330; CYS-374 AND ARG-381, AND CHARACTERIZATION OF VARIANT
RP   OGD CYS-374.
RX   PubMed=15625620; DOI=10.1086/427956;
RA   White K.E., Cabral J.M., Davis S.I., Fishburn T., Evans W.E., Ichikawa S.,
RA   Fields J., Yu X., Shaw N.J., McLellan N.J., McKeown C., FitzPatrick D.,
RA   Yu K., Ornitz D.M., Econs M.J.;
RT   "Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1
RT   in bone elongation.";
RL   Am. J. Hum. Genet. 76:361-367(2005).
RN   [71]
RP   VARIANTS HH2 ILE-102; ALA-129; MET-273 AND THR-520.
RX   PubMed=15605412; DOI=10.1002/humu.9298;
RA   Albuisson J., Pecheux C., Carel J.-C., Lacombe D., Leheup B., Lapuzina P.,
RA   Bouchard P., Legius E., Matthijs G., Wasniewska M., Delpech M., Young J.,
RA   Hardelin J.-P., Dode C.;
RT   "Kallmann syndrome: 14 novel mutations in KAL1 and FGFR1 (KAL2).";
RL   Hum. Mutat. 25:98-99(2005).
RN   [72]
RP   VARIANTS HH2 ARG-687 AND SER-745.
RX   PubMed=15845591; DOI=10.1093/humrep/dei052;
RA   Sato N., Hasegawa T., Hori N., Fukami M., Yoshimura Y., Ogata T.;
RT   "Gonadotrophin therapy in Kallmann syndrome caused by heterozygous
RT   mutations of the gene for fibroblast growth factor receptor 1: report of
RT   three families: case report.";
RL   Hum. Reprod. 20:2173-2178(2005).
RN   [73]
RP   VARIANTS OGD ILE-330 AND ARG-381.
RX   PubMed=16470795; DOI=10.1002/ajmg.a.31106;
RA   Farrow E.G., Davis S.I., Mooney S.D., Beighton P., Mascarenhas L.,
RA   Gutierrez Y.R., Pitukcheewanont P., White K.E.;
RT   "Extended mutational analyses of FGFR1 in osteoglophonic dysplasia.";
RL   Am. J. Med. Genet. A 140:537-539(2006).
RN   [74]
RP   VARIANTS HH2 SER-48; PRO-245; TRP-250; VAL-343; LEU-366; SER-722 AND
RP   ILE-795.
RX   PubMed=16882753; DOI=10.1210/jc.2005-2793;
RA   Trarbach E.B., Costa E.M.F., Versiani B., de Castro M., Baptista M.T.M.,
RA   Garmes H.M., de Mendonca B.B., Latronico A.C.;
RT   "Novel fibroblast growth factor receptor 1 mutations in patients with
RT   congenital hypogonadotropic hypogonadism with and without anosmia.";
RL   J. Clin. Endocrinol. Metab. 91:4006-4012(2006).
RN   [75]
RP   VARIANTS HH2 CYS-78; ILE-102; HIS-224; ASP-237; GLN-254; MET-273; GLY-274
RP   CYS-339; CYS-346; VAL-538; ARG-703 AND SER-703, AND VARIANT VAL-769.
RX   PubMed=16764984; DOI=10.1016/j.mce.2006.04.021;
RA   Pitteloud N., Meysing A., Quinton R., Acierno J.S. Jr., Dwyer A.A.,
RA   Plummer L., Fliers E., Boepple P., Hayes F., Seminara S., Hughes V.A.,
RA   Ma J., Bouloux P., Mohammadi M., Crowley W.F. Jr.;
RT   "Mutations in fibroblast growth factor receptor 1 cause Kallmann syndrome
RT   with a wide spectrum of reproductive phenotypes.";
RL   Mol. Cell. Endocrinol. 254:60-69(2006).
RN   [76]
RP   VARIANTS HH2 SER-178; GLY-622 AND GLN-622.
RX   PubMed=16757108; DOI=10.1016/j.mce.2006.04.006;
RA   Zenaty D., Bretones P., Lambe C., Guemas I., David M., Leger J.,
RA   de Roux N.;
RT   "Paediatric phenotype of Kallmann syndrome due to mutations of fibroblast
RT   growth factor receptor 1 (FGFR1).";
RL   Mol. Cell. Endocrinol. 254:78-83(2006).
RN   [77]
RP   VARIANTS HH2 SER-237; HIS-722 AND LYS-724, AND CHARACTERIZATION OF VARIANTS
RP   HH2 SER-237; HIS-722 AND LYS-724.
RX   PubMed=16606836; DOI=10.1073/pnas.0600962103;
RA   Pitteloud N., Acierno J.S. Jr., Meysing A., Eliseenkova A.V., Ma J.,
RA   Ibrahimi O.A., Metzger D.L., Hayes F.J., Dwyer A.A., Hughes V.A.,
RA   Yialamas M., Hall J.E., Grant E., Mohammadi M., Crowley W.F. Jr.;
RT   "Mutations in fibroblast growth factor receptor 1 cause both Kallmann
RT   syndrome and normosmic idiopathic hypogonadotropic hypogonadism.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:6281-6286(2006).
RN   [78]
RP   VARIANTS HH2 PHE-101; TRP-250; ASP-270; ARG-283; 324-GLU--ARG-822 DEL;
RP   CYS-332; ARG-621; 661-ARG--ARG-822 DEL; PHE-685 AND PHE-693, AND VARIANTS
RP   LYS-77; SER-772 AND CYS-822.
RX   PubMed=17154279; DOI=10.1002/humu.9470;
RA   Dode C., Fouveaut C., Mortier G., Janssens S., Bertherat J., Mahoudeau J.,
RA   Kottler M.-L., Chabrolle C., Gancel A., Francois I., Devriendt K.,
RA   Wolczynski S., Pugeat M., Pineiro-Garcia A., Murat A., Bouchard P.,
RA   Young J., Delpech M., Hardelin J.-P.;
RT   "Novel FGFR1 sequence variants in Kallmann syndrome, and genetic evidence
RT   that the FGFR1c isoform is required in olfactory bulb and palate
RT   morphogenesis.";
RL   Hum. Mutat. 28:97-98(2007).
RN   [79]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-125; THR-252 AND LEU-664.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [80]
RP   VARIANTS HH2 CYS-99; SER-117; ASP-228; THR-239; GLN-250; LEU-470; ASN-618
RP   AND PRO-671, AND CHARACTERIZATION OF VARIANTS HH2 CYS-99; SER-117; ASP-228;
RP   THR-239; GLN-250; LEU-470; ASN-618 AND PRO-671.
RX   PubMed=19820032; DOI=10.1210/jc.2009-0179;
RA   Raivio T., Sidis Y., Plummer L., Chen H., Ma J., Mukherjee A.,
RA   Jacobson-Dickman E., Quinton R., Van Vliet G., Lavoie H., Hughes V.A.,
RA   Dwyer A., Hayes F.J., Xu S., Sparks S., Kaiser U.B., Mohammadi M.,
RA   Pitteloud N.;
RT   "Impaired fibroblast growth factor receptor 1 signaling as a cause of
RT   normosmic idiopathic hypogonadotropic hypogonadism.";
RL   J. Clin. Endocrinol. Metab. 94:4380-4390(2009).
RN   [81]
RP   VARIANT HH2 GLN-250.
RX   PubMed=21700882; DOI=10.1073/pnas.1102284108;
RA   Tornberg J., Sykiotis G.P., Keefe K., Plummer L., Hoang X., Hall J.E.,
RA   Quinton R., Seminara S.B., Hughes V., Van Vliet G., Van Uum S.,
RA   Crowley W.F., Habuchi H., Kimata K., Pitteloud N., Bulow H.E.;
RT   "Heparan sulfate 6-O-sulfotransferase 1, a gene involved in extracellular
RT   sugar modifications, is mutated in patients with idiopathic
RT   hypogonadotrophic hypogonadism.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:11524-11529(2011).
RN   [82]
RP   VARIANT HH2 ARG-687.
RX   PubMed=22927827; DOI=10.1371/journal.pgen.1002896;
RA   Hanchate N.K., Giacobini P., Lhuillier P., Parkash J., Espy C.,
RA   Fouveaut C., Leroy C., Baron S., Campagne C., Vanacker C., Collier F.,
RA   Cruaud C., Meyer V., Garcia-Pinero A., Dewailly D., Cortet-Rudelli C.,
RA   Gersak K., Metz C., Chabrier G., Pugeat M., Young J., Hardelin J.P.,
RA   Prevot V., Dode C.;
RT   "SEMA3A, a gene involved in axonal pathfinding, is mutated in patients with
RT   Kallmann syndrome.";
RL   PLoS Genet. 8:E1002896-E1002896(2012).
RN   [83]
RP   VARIANTS HH2 SER-117; ASP-228; THR-239; GLN-250; SER-342; ARG-348; LEU-470;
RP   THR-483; ASN-618; LYS-670; GLY-692; HIS-722; LYS-724 AND TYR-768.
RX   PubMed=23643382; DOI=10.1016/j.ajhg.2013.04.008;
RA   Miraoui H., Dwyer A.A., Sykiotis G.P., Plummer L., Chung W., Feng B.,
RA   Beenken A., Clarke J., Pers T.H., Dworzynski P., Keefe K., Niedziela M.,
RA   Raivio T., Crowley W.F. Jr., Seminara S.B., Quinton R., Hughes V.A.,
RA   Kumanov P., Young J., Yialamas M.A., Hall J.E., Van Vliet G.,
RA   Chanoine J.P., Rubenstein J., Mohammadi M., Tsai P.S., Sidis Y., Lage K.,
RA   Pitteloud N.;
RT   "Mutations in FGF17, IL17RD, DUSP6, SPRY4, and FLRT3 are identified in
RT   individuals with congenital hypogonadotropic hypogonadism.";
RL   Am. J. Hum. Genet. 92:725-743(2013).
RN   [84]
RP   INVOLVEMENT IN HRTFDS, AND VARIANTS HRTFDS SER-165; SER-191; ARG-490;
RP   TYR-623; LYS-628 AND TYR-725.
RX   PubMed=23812909; DOI=10.1136/jmedgenet-2013-101603;
RA   Simonis N., Migeotte I., Lambert N., Perazzolo C., de Silva D.C.,
RA   Dimitrov B., Heinrichs C., Janssens S., Kerr B., Mortier G., Van Vliet G.,
RA   Lepage P., Casimir G., Abramowicz M., Smits G., Vilain C.;
RT   "FGFR1 mutations cause Hartsfield syndrome, the unique association of
RT   holoprosencephaly and ectrodactyly.";
RL   J. Med. Genet. 50:585-592(2013).
RN   [85]
RP   CHROMOSOMAL TRANSLOCATION WITH RANBP2.
RX   PubMed=23041776; DOI=10.1038/leu.2012.286;
RA   Gervais C., Dano L., Perrusson N., Helias C., Jeandidier E., Galoisy A.C.,
RA   Ittel A., Herbrecht R., Bilger K., Mauvieux L.;
RT   "A translocation t(2;8)(q12;p11) fuses FGFR1 to a novel partner gene,
RT   RANBP2/NUP358, in a myeloproliferative/myelodysplastic neoplasm.";
RL   Leukemia 27:1186-1188(2013).
RN   [86]
RP   VARIANT HRTFDS THR-627.
RX   PubMed=24888332; DOI=10.1002/ajmg.a.36621;
RA   Dhamija R., Kirmani S., Wang X., Ferber M.J., Wieben E.D., Lazaridis K.N.,
RA   Babovic-Vuksanovic D.;
RT   "Novel de novo heterozygous FGFR1 mutation in two siblings with Hartsfield
RT   syndrome: A case of gonadal mosaicism.";
RL   Am. J. Med. Genet. A 164:2356-2359(2014).
RN   [87]
RP   VARIANTS HH2 ARG-70; ILE-116; ALA-174; GLN-250 AND ARG-348.
RX   PubMed=25077900; DOI=10.1210/jc.2014-2110;
RA   Marcos S., Sarfati J., Leroy C., Fouveaut C., Parent P., Metz C.,
RA   Wolczynski S., Gerard M., Bieth E., Kurtz F., Verier-Mine O., Perrin L.,
RA   Archambeaud F., Cabrol S., Rodien P., Hove H., Prescott T., Lacombe D.,
RA   Christin-Maitre S., Touraine P., Hieronimus S., Dewailly D., Young J.,
RA   Pugeat M., Hardelin J.P., Dode C.;
RT   "The prevalence of CHD7 missense versus truncating mutations is higher in
RT   patients with Kallmann syndrome than in typical CHARGE patients.";
RL   J. Clin. Endocrinol. Metab. 99:E2138-2143(2014).
RN   [88]
RP   VARIANTS HH2 CYS-4; CYS-96 AND VAL-719, AND VARIANT HH2 THR-353 (ISOFORM
RP   19).
RX   PubMed=26277103; DOI=10.1016/j.fertnstert.2015.07.1142;
RA   Goncalves C., Bastos M., Pignatelli D., Borges T., Araguees J.M.,
RA   Fonseca F., Pereira B.D., Socorro S., Lemos M.C.;
RT   "Novel FGFR1 mutations in Kallmann syndrome and normosmic idiopathic
RT   hypogonadotropic hypogonadism: evidence for the involvement of an
RT   alternatively spliced isoform.";
RL   Fertil. Steril. 0:0-0(2015).
CC   -!- FUNCTION: Tyrosine-protein kinase that acts as cell-surface receptor
CC       for fibroblast growth factors and plays an essential role in the
CC       regulation of embryonic development, cell proliferation,
CC       differentiation and migration. Required for normal mesoderm patterning
CC       and correct axial organization during embryonic development, normal
CC       skeletogenesis and normal development of the gonadotropin-releasing
CC       hormone (GnRH) neuronal system. Phosphorylates PLCG1, FRS2, GAB1 and
CC       SHB. Ligand binding leads to the activation of several signaling
CC       cascades. Activation of PLCG1 leads to the production of the cellular
CC       signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate.
CC       Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and
CC       SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the
CC       MAP kinase signaling pathway, as well as of the AKT1 signaling pathway.
CC       Promotes phosphorylation of SHC1, STAT1 and PTPN11/SHP2. In the
CC       nucleus, enhances RPS6KA1 and CREB1 activity and contributes to the
CC       regulation of transcription. FGFR1 signaling is down-regulated by
CC       IL17RD/SEF, and by FGFR1 ubiquitination, internalization and
CC       degradation. {ECO:0000250|UniProtKB:P16092,
CC       ECO:0000269|PubMed:10830168, ECO:0000269|PubMed:11353842,
CC       ECO:0000269|PubMed:12181353, ECO:0000269|PubMed:1379697,
CC       ECO:0000269|PubMed:1379698, ECO:0000269|PubMed:15117958,
CC       ECO:0000269|PubMed:16597617, ECO:0000269|PubMed:17311277,
CC       ECO:0000269|PubMed:17623664, ECO:0000269|PubMed:18480409,
CC       ECO:0000269|PubMed:19224897, ECO:0000269|PubMed:19261810,
CC       ECO:0000269|PubMed:19665973, ECO:0000269|PubMed:20133753,
CC       ECO:0000269|PubMed:20139426, ECO:0000269|PubMed:21765395,
CC       ECO:0000269|PubMed:8622701, ECO:0000269|PubMed:8663044}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.1;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028,
CC         ECO:0000269|PubMed:1379697, ECO:0000269|PubMed:15117958,
CC         ECO:0000269|PubMed:18480409, ECO:0000269|PubMed:19224897,
CC         ECO:0000269|PubMed:19665973, ECO:0000269|PubMed:20133753,
CC         ECO:0000269|PubMed:8622701};
CC   -!- ACTIVITY REGULATION: Present in an inactive conformation in the absence
CC       of bound ligand. Ligand binding leads to dimerization and activation by
CC       sequential autophosphorylation on tyrosine residues. Inhibited by ARQ
CC       069; this compound maintains the kinase in an inactive conformation and
CC       inhibits autophosphorylation. Inhibited by PD173074.
CC       {ECO:0000269|PubMed:18480409, ECO:0000269|PubMed:19224897,
CC       ECO:0000269|PubMed:21454610, ECO:0000269|PubMed:8622701}.
CC   -!- SUBUNIT: Monomer. Homodimer after ligand binding. Interacts
CC       predominantly with FGF1 and FGF2, but can also interact with FGF3,
CC       FGF4, FGF5, FGF6, FGF8, FGF10, FGF19, FGF21, FGF22 and FGF23 (in vitro)
CC       (PubMed:1697263, PubMed:1722683, PubMed:8663044, PubMed:9655399,
CC       PubMed:12181353, PubMed:16597617, PubMed:17623664). Ligand specificity
CC       is determined by tissue-specific expression of isoforms, and
CC       differences in the third Ig-like domain are crucial for ligand
CC       specificity. Affinity for fibroblast growth factors (FGFs) is increased
CC       by heparan sulfate glycosaminoglycans that function as coreceptors.
CC       Likewise, KLB increases the affinity for FGF19, FGF21 and FGF23
CC       (PubMed:19966287). Interacts (phosphorylated on Tyr-766) with PLCG1
CC       (via SH2 domains) (PubMed:1656221, PubMed:1379697, PubMed:21765395).
CC       Interacts with FRS2 (PubMed:21765395). Interacts with RPS6KA1
CC       (PubMed:15117958). Interacts (via C-terminus) with NEDD4 (via WW3
CC       domain) (PubMed:21765395). Interacts with KL (By similarity). Interacts
CC       with SHB (via SH2 domain) (PubMed:12181353). Interacts with GRB10
CC       (PubMed:10454568). Interacts with ANOS1; this interaction does not
CC       interfere with FGF2-binding to FGFR1, but prevents binding of heparin-
CC       bound FGF2 (PubMed:19696444). Interacts with SOX2 and SOX3. Interacts
CC       with FLRT1, FLRT2 and FLRT3 (By similarity). Found in a ternary complex
CC       with FGF1 and ITGAV:ITGB3 (PubMed:20422052, PubMed:18441324).
CC       {ECO:0000250|UniProtKB:P16092, ECO:0000269|PubMed:10454568,
CC       ECO:0000269|PubMed:12181353, ECO:0000269|PubMed:1379697,
CC       ECO:0000269|PubMed:15117958, ECO:0000269|PubMed:1656221,
CC       ECO:0000269|PubMed:16597617, ECO:0000269|PubMed:1697263,
CC       ECO:0000269|PubMed:1722683, ECO:0000269|PubMed:17623664,
CC       ECO:0000269|PubMed:18441324, ECO:0000269|PubMed:19696444,
CC       ECO:0000269|PubMed:19966287, ECO:0000269|PubMed:20422052,
CC       ECO:0000269|PubMed:21765395, ECO:0000269|PubMed:8663044,
CC       ECO:0000269|PubMed:9655399}.
CC   -!- INTERACTION:
CC       P11362; P23352: ANOS1; NbExp=7; IntAct=EBI-1028277, EBI-5272188;
CC       P11362; P12830: CDH1; NbExp=3; IntAct=EBI-1028277, EBI-727477;
CC       P11362; P05230: FGF1; NbExp=4; IntAct=EBI-1028277, EBI-698068;
CC       P11362; P09038: FGF2; NbExp=7; IntAct=EBI-1028277, EBI-977447;
CC       P11362; Q9GZV9: FGF23; NbExp=2; IntAct=EBI-1028277, EBI-6594125;
CC       P11362; P11362: FGFR1; NbExp=4; IntAct=EBI-1028277, EBI-1028277;
CC       P11362; P08238: HSP90AB1; NbExp=2; IntAct=EBI-1028277, EBI-352572;
CC       P11362; P08908: HTR1A; NbExp=9; IntAct=EBI-1028277, EBI-6570214;
CC       P11362; P46934: NEDD4; NbExp=26; IntAct=EBI-1028277, EBI-726944;
CC       P11362; Q8IVI9: NOSTRIN; NbExp=5; IntAct=EBI-1028277, EBI-1391643;
CC       P11362; P27986: PIK3R1; NbExp=5; IntAct=EBI-1028277, EBI-79464;
CC       P11362; P19174: PLCG1; NbExp=9; IntAct=EBI-1028277, EBI-79387;
CC       P11362; O88900: Grb14; Xeno; NbExp=3; IntAct=EBI-1028277, EBI-7639197;
CC       P11362; O35082: Kl; Xeno; NbExp=2; IntAct=EBI-1028277, EBI-1570828;
CC       P11362; P10686: Plcg1; Xeno; NbExp=4; IntAct=EBI-1028277, EBI-520788;
CC       P11362-2; Q02363: ID2; NbExp=3; IntAct=EBI-25852941, EBI-713450;
CC       P11362-2; Q9BRX2: PELO; NbExp=3; IntAct=EBI-25852941, EBI-1043580;
CC       P11362-7; P09038: FGF2; NbExp=2; IntAct=EBI-15609945, EBI-977447;
CC       P11362-7; O35082: Kl; Xeno; NbExp=3; IntAct=EBI-15609945, EBI-1570828;
CC       P11362-14; P09038: FGF2; NbExp=2; IntAct=EBI-6622185, EBI-977447;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein. Nucleus. Cytoplasm, cytosol. Cytoplasmic vesicle. Note=After
CC       ligand binding, both receptor and ligand are rapidly internalized. Can
CC       translocate to the nucleus after internalization, or by translocation
CC       from the endoplasmic reticulum or Golgi apparatus to the cytosol, and
CC       from there to the nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=21;
CC       Name=1; Synonyms=Alpha A1, IV;
CC         IsoId=P11362-1; Sequence=Displayed;
CC       Name=2; Synonyms=Alpha A2;
CC         IsoId=P11362-8; Sequence=VSP_009842, VSP_009843;
CC       Name=3; Synonyms=Alpha A3;
CC         IsoId=P11362-17; Sequence=VSP_009836, VSP_009837;
CC       Name=4; Synonyms=Alpha B1;
CC         IsoId=P11362-2; Sequence=VSP_002960;
CC       Name=5; Synonyms=Alpha B2;
CC         IsoId=P11362-9; Sequence=VSP_002960, VSP_009842, VSP_009843;
CC       Name=6; Synonyms=Beta A1, II, H2;
CC         IsoId=P11362-3; Sequence=VSP_002958;
CC       Name=7; Synonyms=Beta A2;
CC         IsoId=P11362-10; Sequence=VSP_002958, VSP_009842, VSP_009843;
CC       Name=8; Synonyms=Beta B1;
CC         IsoId=P11362-4; Sequence=VSP_002958, VSP_002960;
CC       Name=9; Synonyms=Beta B2;
CC         IsoId=P11362-11; Sequence=VSP_002958, VSP_002960, VSP_009842,
CC                                   VSP_009843;
CC       Name=10; Synonyms=Gamma A1;
CC         IsoId=P11362-5; Sequence=VSP_002957;
CC       Name=11; Synonyms=Gamma A2;
CC         IsoId=P11362-12; Sequence=VSP_002957, VSP_009842, VSP_009843;
CC       Name=12; Synonyms=Gamma B1;
CC         IsoId=P11362-6; Sequence=VSP_002957, VSP_002960;
CC       Name=13; Synonyms=Gamma B2;
CC         IsoId=P11362-13; Sequence=VSP_002957, VSP_002960, VSP_009842,
CC                                   VSP_009843;
CC       Name=14; Synonyms=A, III;
CC         IsoId=P11362-7; Sequence=VSP_002959;
CC       Name=15; Synonyms=I, H3;
CC         IsoId=P11362-14; Sequence=VSP_002958, VSP_002959;
CC       Name=16; Synonyms=V;
CC         IsoId=P11362-15; Sequence=VSP_009838, VSP_009839;
CC       Name=17; Synonyms=H4;
CC         IsoId=P11362-16; Sequence=VSP_002958, VSP_009840, VSP_009841;
CC       Name=18; Synonyms=H5;
CC         IsoId=P11362-18; Sequence=VSP_002958, VSP_002959, VSP_009840,
CC                                   VSP_009841;
CC       Name=19;
CC         IsoId=P11362-19; Sequence=VSP_038470, VSP_002959, VSP_038471;
CC       Name=20;
CC         IsoId=P11362-20; Sequence=VSP_041916, VSP_041918;
CC       Name=21;
CC         IsoId=P11362-21; Sequence=VSP_041917, VSP_002959;
CC   -!- TISSUE SPECIFICITY: Detected in astrocytoma, neuroblastoma and adrenal
CC       cortex cell lines. Some isoforms are detected in foreskin fibroblast
CC       cell lines, however isoform 17, isoform 18 and isoform 19 are not
CC       detected in these cells. {ECO:0000269|PubMed:1652059}.
CC   -!- DOMAIN: The second and third Ig-like domains directly interact with
CC       fibroblast growth factors (FGF) and heparan sulfate proteoglycans.
CC       Isoforms lacking the first Ig-like domain have higher affinity for
CC       fibroblast growth factors (FGF) and heparan sulfate proteoglycans than
CC       isoforms with all three Ig-like domains.
CC   -!- PTM: Autophosphorylated. Binding of FGF family members together with
CC       heparan sulfate proteoglycan or heparin promotes receptor dimerization
CC       and autophosphorylation on tyrosine residues. Autophosphorylation
CC       occurs in trans between the two FGFR molecules present in the dimer and
CC       proceeds in a highly ordered manner. Initial autophosphorylation at
CC       Tyr-653 increases the kinase activity by a factor of 50 to 100. After
CC       this, Tyr-583 becomes phosphorylated, followed by phosphorylation of
CC       Tyr-463, Tyr-766, Tyr-583 and Tyr-585. In a third stage, Tyr-654 is
CC       autophosphorylated, resulting in a further tenfold increase of kinase
CC       activity. Phosphotyrosine residues provide docking sites for
CC       interacting proteins and so are crucial for FGFR1 function and its
CC       regulation. {ECO:0000269|PubMed:16507368, ECO:0000269|PubMed:19224897,
CC       ECO:0000269|PubMed:19665973, ECO:0000269|PubMed:8622701}.
CC   -!- PTM: Ubiquitinated. FGFR1 is rapidly ubiquitinated by NEDD4 after
CC       autophosphorylation, leading to internalization and lysosomal
CC       degradation. CBL is recruited to activated FGFR1 via FRS2 and GRB2, and
CC       mediates ubiquitination and subsequent degradation of FGFR1.
CC       {ECO:0000269|PubMed:18480409, ECO:0000269|PubMed:21765395}.
CC   -!- PTM: N-glycosylated in the endoplasmic reticulum. The N-glycan chains
CC       undergo further maturation to an Endo H-resistant form in the Golgi
CC       apparatus. {ECO:0000269|PubMed:16335952, ECO:0000269|PubMed:16481405,
CC       ECO:0000269|PubMed:17311277}.
CC   -!- DISEASE: Jackson-Weiss syndrome (JWS) [MIM:123150]: An autosomal
CC       dominant craniosynostosis syndrome characterized by craniofacial
CC       abnormalities and abnormality of the feet: broad great toes with medial
CC       deviation and tarsal-metatarsal coalescence.
CC       {ECO:0000269|PubMed:10861678}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Fibroblast growth factor receptor subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAD92156.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/FGFR1ID113.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/fgfr1/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M37722; AAA75007.1; -; mRNA.
DR   EMBL; X52833; CAA37015.1; -; mRNA.
DR   EMBL; M34185; AAA35836.1; -; mRNA.
DR   EMBL; M34186; AAA35837.1; -; mRNA.
DR   EMBL; M34187; AAA35838.1; -; mRNA.
DR   EMBL; M34188; AAA35839.1; -; mRNA.
DR   EMBL; X51803; CAA36101.1; -; mRNA.
DR   EMBL; M34641; AAA35835.1; -; mRNA.
DR   EMBL; M60485; AAA35840.1; -; mRNA.
DR   EMBL; X57118; CAA40400.1; -; mRNA.
DR   EMBL; X57119; CAA40401.1; -; mRNA.
DR   EMBL; X57120; CAA40402.1; -; mRNA.
DR   EMBL; X57121; CAA40403.1; -; mRNA.
DR   EMBL; X57122; CAA40404.1; -; mRNA.
DR   EMBL; M63887; AAA35958.1; -; mRNA.
DR   EMBL; M63888; AAA35959.1; -; mRNA.
DR   EMBL; M63889; AAA35960.1; -; mRNA.
DR   EMBL; X66945; CAA47375.1; -; mRNA.
DR   EMBL; FJ809917; ACO38646.1; -; mRNA.
DR   EMBL; AK291754; BAF84443.1; -; mRNA.
DR   EMBL; AK292470; BAF85159.1; -; mRNA.
DR   EMBL; AK309947; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AB208919; BAD92156.1; ALT_INIT; mRNA.
DR   EMBL; AK222718; BAD96438.1; -; mRNA.
DR   EMBL; AY585209; AAS79322.1; -; Genomic_DNA.
DR   EMBL; AC087623; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC015035; AAH15035.1; -; mRNA.
DR   EMBL; BC018128; AAH18128.1; -; mRNA.
DR   EMBL; BC091494; AAH91494.1; -; mRNA.
DR   EMBL; Y00665; CAA68679.1; -; mRNA.
DR   CCDS; CCDS43730.1; -. [P11362-3]
DR   CCDS; CCDS43731.1; -. [P11362-14]
DR   CCDS; CCDS43732.1; -. [P11362-7]
DR   CCDS; CCDS55221.1; -. [P11362-20]
DR   CCDS; CCDS55222.1; -. [P11362-2]
DR   CCDS; CCDS55223.1; -. [P11362-21]
DR   CCDS; CCDS6107.2; -. [P11362-1]
DR   PIR; A41266; A41266.
DR   PIR; C36464; C36464.
DR   PIR; C40862; C40862.
DR   PIR; S11692; TVHUFG.
DR   PIR; S19167; A40862.
DR   RefSeq; NP_001167534.1; NM_001174063.1. [P11362-2]
DR   RefSeq; NP_001167535.1; NM_001174064.1. [P11362-20]
DR   RefSeq; NP_001167536.1; NM_001174065.1. [P11362-7]
DR   RefSeq; NP_001167537.1; NM_001174066.1. [P11362-3]
DR   RefSeq; NP_001167538.1; NM_001174067.1. [P11362-21]
DR   RefSeq; NP_056934.2; NM_015850.3. [P11362-7]
DR   RefSeq; NP_075593.1; NM_023105.2. [P11362-3]
DR   RefSeq; NP_075594.1; NM_023106.2. [P11362-14]
DR   RefSeq; NP_075598.2; NM_023110.2. [P11362-1]
DR   PDB; 1AGW; X-ray; 2.40 A; A/B=456-765.
DR   PDB; 1CVS; X-ray; 2.80 A; C/D=141-365.
DR   PDB; 1EVT; X-ray; 2.80 A; C/D=141-365.
DR   PDB; 1FGI; X-ray; 2.50 A; A/B=456-765.
DR   PDB; 1FGK; X-ray; 2.00 A; A/B=456-765.
DR   PDB; 1FQ9; X-ray; 3.00 A; C/D=141-365.
DR   PDB; 1XR0; NMR; -; A=409-430.
DR   PDB; 2CR3; NMR; -; A=38-123.
DR   PDB; 2FGI; X-ray; 2.50 A; A/B=456-765.
DR   PDB; 3C4F; X-ray; 2.07 A; A/B=464-765.
DR   PDB; 3DPK; X-ray; 1.95 A; A=577-615.
DR   PDB; 3GQI; X-ray; 2.50 A; A=458-774.
DR   PDB; 3GQL; X-ray; 2.80 A; A/B/C=458-774.
DR   PDB; 3JS2; X-ray; 2.20 A; A/B=458-765.
DR   PDB; 3KRJ; X-ray; 2.10 A; A=577-597.
DR   PDB; 3KRL; X-ray; 2.40 A; A=577-597.
DR   PDB; 3KXX; X-ray; 3.20 A; A/B/C/D=458-765.
DR   PDB; 3KY2; X-ray; 2.70 A; A/B=458-765.
DR   PDB; 3OJV; X-ray; 2.60 A; C/D=142-365.
DR   PDB; 3RHX; X-ray; 2.01 A; A/B=461-765.
DR   PDB; 3TT0; X-ray; 2.80 A; A/B=456-765.
DR   PDB; 4F63; X-ray; 2.55 A; A/B=458-765.
DR   PDB; 4F64; X-ray; 2.05 A; A/B=458-765.
DR   PDB; 4F65; X-ray; 2.26 A; A/B=458-765.
DR   PDB; 4NK9; X-ray; 2.57 A; A/B=458-765.
DR   PDB; 4NKA; X-ray; 2.19 A; A/B=458-765.
DR   PDB; 4NKS; X-ray; 2.50 A; A/B=458-765.
DR   PDB; 4RWI; X-ray; 2.29 A; A/B=458-765.
DR   PDB; 4RWJ; X-ray; 2.49 A; A/B=458-765.
DR   PDB; 4RWK; X-ray; 2.98 A; A/B=458-765.
DR   PDB; 4RWL; X-ray; 2.19 A; A/B=458-765.
DR   PDB; 4UWB; X-ray; 2.31 A; A/B=458-765.
DR   PDB; 4UWC; X-ray; 1.96 A; A/B=458-765.
DR   PDB; 4UWY; X-ray; 2.31 A; A/B=458-765.
DR   PDB; 4V01; X-ray; 2.33 A; A/B=458-765.
DR   PDB; 4V04; X-ray; 2.12 A; A/B=458-765.
DR   PDB; 4V05; X-ray; 2.57 A; A/B=458-765.
DR   PDB; 4WUN; X-ray; 1.65 A; A/B=459-765.
DR   PDB; 4ZSA; X-ray; 2.00 A; A/B=458-765.
DR   PDB; 5A46; X-ray; 2.63 A; A/B=437-822.
DR   PDB; 5A4C; X-ray; 2.09 A; A/B=461-765.
DR   PDB; 5AM6; X-ray; 1.96 A; A/B=458-765.
DR   PDB; 5AM7; X-ray; 1.96 A; A/B=458-765.
DR   PDB; 5B7V; X-ray; 2.15 A; A/B=456-765.
DR   PDB; 5EW8; X-ray; 1.63 A; A/B=458-765.
DR   PDB; 5FLF; X-ray; 2.58 A; A/B/C/D/E=458-765.
DR   PDB; 5O49; X-ray; 1.91 A; A/B=458-765.
DR   PDB; 5O4A; X-ray; 2.01 A; A/B=458-765.
DR   PDB; 5UQ0; X-ray; 2.30 A; A/B=459-765.
DR   PDB; 5UR1; X-ray; 2.20 A; A/B=459-765.
DR   PDB; 5VND; X-ray; 2.20 A; A/B=458-765.
DR   PDB; 5W21; X-ray; 3.00 A; C=142-365.
DR   PDB; 5W59; X-ray; 2.50 A; B=142-365.
DR   PDB; 5Z0S; X-ray; 2.45 A; A/B=458-765.
DR   PDB; 5ZV2; X-ray; 2.86 A; A/B=461-764.
DR   PDB; 6C18; X-ray; 2.30 A; A/B=459-765.
DR   PDB; 6C19; X-ray; 2.12 A; A/B=459-765.
DR   PDB; 6C1B; X-ray; 2.00 A; A/B=459-765.
DR   PDB; 6C1C; X-ray; 2.15 A; A/B=459-765.
DR   PDB; 6C1O; X-ray; 2.29 A; A/B=459-765.
DR   PDB; 6ITJ; X-ray; 1.99 A; A/B=458-765.
DR   PDB; 6MZQ; X-ray; 2.00 A; A/B=459-765.
DR   PDB; 6MZW; X-ray; 2.20 A; A/B=459-765.
DR   PDB; 6NVL; X-ray; 2.70 A; A/B/C/D=458-765.
DR   PDB; 6P68; X-ray; 2.90 A; A/B/C=458-765.
DR   PDB; 6P69; X-ray; 2.20 A; A/B=458-765.
DR   PDBsum; 1AGW; -.
DR   PDBsum; 1CVS; -.
DR   PDBsum; 1EVT; -.
DR   PDBsum; 1FGI; -.
DR   PDBsum; 1FGK; -.
DR   PDBsum; 1FQ9; -.
DR   PDBsum; 1XR0; -.
DR   PDBsum; 2CR3; -.
DR   PDBsum; 2FGI; -.
DR   PDBsum; 3C4F; -.
DR   PDBsum; 3DPK; -.
DR   PDBsum; 3GQI; -.
DR   PDBsum; 3GQL; -.
DR   PDBsum; 3JS2; -.
DR   PDBsum; 3KRJ; -.
DR   PDBsum; 3KRL; -.
DR   PDBsum; 3KXX; -.
DR   PDBsum; 3KY2; -.
DR   PDBsum; 3OJV; -.
DR   PDBsum; 3RHX; -.
DR   PDBsum; 3TT0; -.
DR   PDBsum; 4F63; -.
DR   PDBsum; 4F64; -.
DR   PDBsum; 4F65; -.
DR   PDBsum; 4NK9; -.
DR   PDBsum; 4NKA; -.
DR   PDBsum; 4NKS; -.
DR   PDBsum; 4RWI; -.
DR   PDBsum; 4RWJ; -.
DR   PDBsum; 4RWK; -.
DR   PDBsum; 4RWL; -.
DR   PDBsum; 4UWB; -.
DR   PDBsum; 4UWC; -.
DR   PDBsum; 4UWY; -.
DR   PDBsum; 4V01; -.
DR   PDBsum; 4V04; -.
DR   PDBsum; 4V05; -.
DR   PDBsum; 4WUN; -.
DR   PDBsum; 4ZSA; -.
DR   PDBsum; 5A46; -.
DR   PDBsum; 5A4C; -.
DR   PDBsum; 5AM6; -.
DR   PDBsum; 5AM7; -.
DR   PDBsum; 5B7V; -.
DR   PDBsum; 5EW8; -.
DR   PDBsum; 5FLF; -.
DR   PDBsum; 5O49; -.
DR   PDBsum; 5O4A; -.
DR   PDBsum; 5UQ0; -.
DR   PDBsum; 5UR1; -.
DR   PDBsum; 5VND; -.
DR   PDBsum; 5W21; -.
DR   PDBsum; 5W59; -.
DR   PDBsum; 5Z0S; -.
DR   PDBsum; 5ZV2; -.
DR   PDBsum; 6C18; -.
DR   PDBsum; 6C19; -.
DR   PDBsum; 6C1B; -.
DR   PDBsum; 6C1C; -.
DR   PDBsum; 6C1O; -.
DR   PDBsum; 6ITJ; -.
DR   PDBsum; 6MZQ; -.
DR   PDBsum; 6MZW; -.
DR   PDBsum; 6NVL; -.
DR   PDBsum; 6P68; -.
DR   PDBsum; 6P69; -.
DR   BMRB; P11362; -.
DR   SMR; P11362; -.
DR   BioGRID; 108551; 241.
DR   CORUM; P11362; -.
DR   DIP; DIP-4019N; -.
DR   IntAct; P11362; 165.
DR   MINT; P11362; -.
DR   STRING; 9606.ENSP00000393312; -.
DR   BindingDB; P11362; -.
DR   ChEMBL; CHEMBL3650; -.
DR   DrugBank; DB07840; (E)-[4-(3,5-Difluorophenyl)-3H-pyrrolo[2,3-b]pyridin-3-ylidene](3-methoxyphenyl)methanol.
DR   DrugBank; DB07525; 3-(3-methoxybenzyl)-1H-pyrrolo[2,3-b]pyridine.
DR   DrugBank; DB08577; 3-[(3-(2-CARBOXYETHYL)-4-METHYLPYRROL-2-YL)METHYLENE]-2-INDOLINONE.
DR   DrugBank; DB02058; 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone.
DR   DrugBank; DB12147; Erdafitinib.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB01109; Heparin.
DR   DrugBank; DB09078; Lenvatinib.
DR   DrugBank; DB09079; Nintedanib.
DR   DrugBank; DB00039; Palifermin.
DR   DrugBank; DB15102; Pemigatinib.
DR   DrugBank; DB08901; Ponatinib.
DR   DrugBank; DB15822; Pralsetinib.
DR   DrugBank; DB08896; Regorafenib.
DR   DrugBank; DB15685; Selpercatinib.
DR   DrugBank; DB00398; Sorafenib.
DR   DrugBank; DB05014; XL999.
DR   DrugCentral; P11362; -.
DR   GuidetoPHARMACOLOGY; 1808; -.
DR   TCDB; 8.A.23.1.7; the basigin (basigin) family.
DR   CarbonylDB; P11362; -.
DR   GlyConnect; 1239; 8 N-Linked glycans (4 sites).
DR   GlyGen; P11362; 11 sites, 11 N-linked glycans (5 sites).
DR   iPTMnet; P11362; -.
DR   PhosphoSitePlus; P11362; -.
DR   SwissPalm; P11362; -.
DR   BioMuta; FGFR1; -.
DR   DMDM; 120046; -.
DR   CPTAC; CPTAC-1773; -.
DR   CPTAC; CPTAC-1780; -.
DR   EPD; P11362; -.
DR   jPOST; P11362; -.
DR   MassIVE; P11362; -.
DR   MaxQB; P11362; -.
DR   PaxDb; P11362; -.
DR   PeptideAtlas; P11362; -.
DR   PRIDE; P11362; -.
DR   ProteomicsDB; 52745; -. [P11362-1]
DR   ProteomicsDB; 52746; -. [P11362-10]
DR   ProteomicsDB; 52747; -. [P11362-11]
DR   ProteomicsDB; 52748; -. [P11362-12]
DR   ProteomicsDB; 52749; -. [P11362-13]
DR   ProteomicsDB; 52750; -. [P11362-14]
DR   ProteomicsDB; 52751; -. [P11362-15]
DR   ProteomicsDB; 52752; -. [P11362-16]
DR   ProteomicsDB; 52753; -. [P11362-17]
DR   ProteomicsDB; 52754; -. [P11362-18]
DR   ProteomicsDB; 52755; -. [P11362-19]
DR   ProteomicsDB; 52756; -. [P11362-2]
DR   ProteomicsDB; 52757; -. [P11362-20]
DR   ProteomicsDB; 52758; -. [P11362-21]
DR   ProteomicsDB; 52759; -. [P11362-3]
DR   ProteomicsDB; 52760; -. [P11362-4]
DR   ProteomicsDB; 52761; -. [P11362-5]
DR   ProteomicsDB; 52762; -. [P11362-6]
DR   ProteomicsDB; 52763; -. [P11362-7]
DR   ProteomicsDB; 52764; -. [P11362-8]
DR   ProteomicsDB; 52765; -. [P11362-9]
DR   Antibodypedia; 11015; 2455 antibodies.
DR   DNASU; 2260; -.
DR   Ensembl; ENST00000326324; ENSP00000327229; ENSG00000077782. [P11362-14]
DR   Ensembl; ENST00000335922; ENSP00000337247; ENSG00000077782. [P11362-20]
DR   Ensembl; ENST00000356207; ENSP00000348537; ENSG00000077782. [P11362-3]
DR   Ensembl; ENST00000397091; ENSP00000380280; ENSG00000077782. [P11362-7]
DR   Ensembl; ENST00000397108; ENSP00000380297; ENSG00000077782. [P11362-7]
DR   Ensembl; ENST00000397113; ENSP00000380302; ENSG00000077782. [P11362-7]
DR   Ensembl; ENST00000447712; ENSP00000400162; ENSG00000077782. [P11362-1]
DR   Ensembl; ENST00000484370; ENSP00000433163; ENSG00000077782. [P11362-15]
DR   Ensembl; ENST00000532791; ENSP00000432972; ENSG00000077782. [P11362-2]
DR   GeneID; 2260; -.
DR   UCSC; uc003xlp.4; human. [P11362-1]
DR   CTD; 2260; -.
DR   DisGeNET; 2260; -.
DR   GeneCards; FGFR1; -.
DR   GeneReviews; FGFR1; -.
DR   HGNC; HGNC:3688; FGFR1.
DR   HPA; ENSG00000077782; Low tissue specificity.
DR   MalaCards; FGFR1; -.
DR   MIM; 101600; phenotype.
DR   MIM; 123150; phenotype.
DR   MIM; 136350; gene.
DR   MIM; 147950; phenotype.
DR   MIM; 166250; phenotype.
DR   MIM; 190440; phenotype.
DR   MIM; 613001; phenotype.
DR   MIM; 615465; phenotype.
DR   neXtProt; NX_P11362; -.
DR   OpenTargets; ENSG00000077782; -.
DR   Orphanet; 2396; Encephalocraniocutaneous lipomatosis.
DR   Orphanet; 251579; Giant cell glioblastoma.
DR   Orphanet; 251576; Gliosarcoma.
DR   Orphanet; 2117; Hartsfield syndrome.
DR   Orphanet; 3366; Isolated trigonocephaly.
DR   Orphanet; 478; Kallmann syndrome.
DR   Orphanet; 93924; Lobar holoprosencephaly.
DR   Orphanet; 280200; Microform holoprosencephaly.
DR   Orphanet; 168953; Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement.
DR   Orphanet; 2227; NON RARE IN EUROPE: Hypodontia.
DR   Orphanet; 432; Normosmic congenital hypogonadotropic hypogonadism.
DR   Orphanet; 99798; Oligodontia.
DR   Orphanet; 2645; Osteoglosphonic dysplasia.
DR   Orphanet; 93258; Pfeiffer syndrome type 1.
DR   Orphanet; 251615; Pilomyxoid astrocytoma.
DR   Orphanet; 314950; Primary hypereosinophilic syndrome.
DR   Orphanet; 220386; Semilobar holoprosencephaly.
DR   Orphanet; 3157; Septo-optic dysplasia spectrum.
DR   PharmGKB; PA28127; -.
DR   VEuPathDB; HostDB:ENSG00000077782; -.
DR   eggNOG; KOG0200; Eukaryota.
DR   GeneTree; ENSGT00940000155860; -.
DR   HOGENOM; CLU_000288_74_3_1; -.
DR   InParanoid; P11362; -.
DR   OMA; RCLILWA; -.
DR   OrthoDB; 220433at2759; -.
DR   PhylomeDB; P11362; -.
DR   TreeFam; TF316307; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   PathwayCommons; P11362; -.
DR   Reactome; R-HSA-109704; PI3K Cascade.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-1839120; Signaling by FGFR1 amplification mutants.
DR   Reactome; R-HSA-1839122; Signaling by activated point mutants of FGFR1.
DR   Reactome; R-HSA-190370; FGFR1b ligand binding and activation. [P11362-19]
DR   Reactome; R-HSA-190373; FGFR1c ligand binding and activation. [P11362-1]
DR   Reactome; R-HSA-190374; FGFR1c and Klotho ligand binding and activation. [P11362-1]
DR   Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer.
DR   Reactome; R-HSA-375165; NCAM signaling for neurite out-growth. [P11362-1]
DR   Reactome; R-HSA-445144; Signal transduction by L1. [P11362-1]
DR   Reactome; R-HSA-5654219; Phospholipase C-mediated cascade: FGFR1.
DR   Reactome; R-HSA-5654687; Downstream signaling of activated FGFR1.
DR   Reactome; R-HSA-5654688; SHC-mediated cascade:FGFR1.
DR   Reactome; R-HSA-5654689; PI-3K cascade:FGFR1.
DR   Reactome; R-HSA-5654693; FRS-mediated FGFR1 signaling.
DR   Reactome; R-HSA-5654726; Negative regulation of FGFR1 signaling.
DR   Reactome; R-HSA-5655302; Signaling by FGFR1 in disease.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   Reactome; R-HSA-8853336; Signaling by plasma membrane FGFR1 fusions.
DR   SignaLink; P11362; -.
DR   SIGNOR; P11362; -.
DR   BioGRID-ORCS; 2260; 62 hits in 1048 CRISPR screens.
DR   ChiTaRS; FGFR1; human.
DR   EvolutionaryTrace; P11362; -.
DR   GeneWiki; Fibroblast_growth_factor_receptor_1; -.
DR   GenomeRNAi; 2260; -.
DR   Pharos; P11362; Tclin.
DR   PRO; PR:P11362; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   RNAct; P11362; protein.
DR   Bgee; ENSG00000077782; Expressed in body of pancreas and 251 other tissues.
DR   ExpressionAtlas; P11362; baseline and differential.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IEA:UniProtKB-KW.
DR   GO; GO:0005829; C:cytosol; IEA:UniProtKB-SubCell.
DR   GO; GO:0005576; C:extracellular region; NAS:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; NAS:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0017134; F:fibroblast growth factor binding; IDA:UniProtKB.
DR   GO; GO:0005007; F:fibroblast growth factor-activated receptor activity; IDA:UniProtKB.
DR   GO; GO:0008201; F:heparin binding; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0090722; F:receptor-receptor interaction; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IBA:GO_Central.
DR   GO; GO:0016477; P:cell migration; TAS:UniProtKB.
DR   GO; GO:0043009; P:chordate embryonic development; TAS:UniProtKB.
DR   GO; GO:0001837; P:epithelial to mesenchymal transition; IMP:BHF-UCL.
DR   GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0000165; P:MAPK cascade; TAS:ProtInc.
DR   GO; GO:0001764; P:neuron migration; TAS:UniProtKB.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; TAS:UniProtKB.
DR   GO; GO:0043536; P:positive regulation of blood vessel endothelial cell migration; IGI:BHF-UCL.
DR   GO; GO:0045597; P:positive regulation of cell differentiation; IBA:GO_Central.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:UniProtKB.
DR   GO; GO:2000546; P:positive regulation of endothelial cell chemotaxis to fibroblast growth factor; IDA:BHF-UCL.
DR   GO; GO:0033674; P:positive regulation of kinase activity; IBA:GO_Central.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; IDA:UniProtKB.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IMP:UniProtKB.
DR   GO; GO:0045666; P:positive regulation of neuron differentiation; IMP:UniProtKB.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; TAS:UniProtKB.
DR   GO; GO:0010518; P:positive regulation of phospholipase activity; TAS:UniProtKB.
DR   GO; GO:0010863; P:positive regulation of phospholipase C activity; IDA:UniProtKB.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IGI:BHF-UCL.
DR   GO; GO:1905564; P:positive regulation of vascular endothelial cell proliferation; IGI:BHF-UCL.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; NAS:UniProtKB.
DR   GO; GO:0045595; P:regulation of cell differentiation; TAS:UniProtKB.
DR   GO; GO:2001239; P:regulation of extrinsic apoptotic signaling pathway in absence of ligand; TAS:BHF-UCL.
DR   GO; GO:0001501; P:skeletal system development; TAS:ProtInc.
DR   GO; GO:0048705; P:skeletal system morphogenesis; TAS:UniProtKB.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   CDD; cd05098; PTKc_FGFR1; 1.
DR   Gene3D; 2.60.40.10; -; 3.
DR   IDEAL; IID00650; -.
DR   InterPro; IPR028174; FGF_rcpt_1.
DR   InterPro; IPR016248; FGF_rcpt_fam.
DR   InterPro; IPR041159; FGFR_TM.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR036179; Ig-like_dom_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR013151; Immunoglobulin.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   Pfam; PF18123; FGFR3_TM; 1.
DR   Pfam; PF07679; I-set; 2.
DR   Pfam; PF00047; ig; 1.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   PIRSF; PIRSF000628; FGFR; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00409; IG; 3.
DR   SMART; SM00408; IGc2; 3.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 3.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50835; IG_LIKE; 3.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
FT   SIGNAL          1..21
FT   CHAIN           22..822
FT                   /note="Fibroblast growth factor receptor 1"
FT                   /id="PRO_0000016780"
FT   TOPO_DOM        22..376
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        377..397
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        398..822
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          25..119
FT                   /note="Ig-like C2-type 1"
FT   DOMAIN          158..246
FT                   /note="Ig-like C2-type 2"
FT   DOMAIN          255..357
FT                   /note="Ig-like C2-type 3"
FT   DOMAIN          478..767
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   NP_BIND         484..490
FT                   /note="ATP"
FT   NP_BIND         562..564
FT                   /note="ATP"
FT   REGION          120..154
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          160..177
FT                   /note="Heparin-binding"
FT   REGION          778..822
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        123..137
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        778..794
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        623
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028,
FT                   ECO:0000269|PubMed:19224897"
FT   BINDING         514
FT                   /note="ATP"
FT   BINDING         568
FT                   /note="ATP"
FT   BINDING         627
FT                   /note="ATP"
FT   BINDING         641
FT                   /note="ATP"
FT   SITE            428..429
FT                   /note="Breakpoint for translocation to form CEP43-FGFR1 or
FT                   FGFR1-CEP43 fusion proteins"
FT                   /evidence="ECO:0000269|PubMed:9949182"
FT   SITE            428..429
FT                   /note="Breakpoint for translocation to form CNTRL-FGFR1 OR
FT                   FGFR1-CNTRL fusion proteins"
FT                   /evidence="ECO:0000269|PubMed:10688839"
FT   SITE            428..429
FT                   /note="Breakpoint for translocation to form FGFR1OP2-FGFR1"
FT                   /evidence="ECO:0000269|PubMed:15034873,
FT                   ECO:0000269|PubMed:16946300, ECO:0000269|PubMed:17389761"
FT   SITE            766
FT                   /note="Mediates interaction with PLCG1 and SHB"
FT   MOD_RES         463
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:16507368,
FT                   ECO:0000269|PubMed:19224897, ECO:0000269|PubMed:8622701"
FT   MOD_RES         583
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:16507368,
FT                   ECO:0000269|PubMed:19224897, ECO:0000269|PubMed:8622701"
FT   MOD_RES         585
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:16507368,
FT                   ECO:0000269|PubMed:19224897, ECO:0000269|PubMed:8622701"
FT   MOD_RES         653
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:16507368,
FT                   ECO:0000269|PubMed:19224897, ECO:0000269|PubMed:19665973,
FT                   ECO:0000269|PubMed:8622701"
FT   MOD_RES         654
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:16507368,
FT                   ECO:0000269|PubMed:19224897, ECO:0000269|PubMed:19665973,
FT                   ECO:0000269|PubMed:8622701"
FT   MOD_RES         730
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:19224897,
FT                   ECO:0000269|PubMed:8622701"
FT   MOD_RES         766
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:19665973"
FT   CARBOHYD        77
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        117
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        227
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        240
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        264
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        296
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16335952"
FT   CARBOHYD        317
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        330
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        55..101
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DISULFID        178..230
FT   DISULFID        277..341
FT   VAR_SEQ         1..160
FT                   /note="Missing (in isoform 10, isoform 11, isoform 12 and
FT                   isoform 13)"
FT                   /evidence="ECO:0000303|PubMed:1846977"
FT                   /id="VSP_002957"
FT   VAR_SEQ         1..30
FT                   /note="MWSWKCLLFWAVLVTATLCTARPSPTLPEQ -> MAAVTRDFGEMLLHSGRV
FT                   LPAE (in isoform 20)"
FT                   /evidence="ECO:0000303|Ref.12"
FT                   /id="VSP_041916"
FT   VAR_SEQ         1
FT                   /note="M -> MEARVSLKRRIELTVEYPWRCGALSPTSNCRTGM (in isoform
FT                   21)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_041917"
FT   VAR_SEQ         31..119
FT                   /note="Missing (in isoform 6, isoform 7, isoform 8, isoform
FT                   9, isoform 15, isoform 17 and isoform 18)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:1650441,
FT                   ECO:0000303|PubMed:1846977, ECO:0000303|PubMed:2162671,
FT                   ECO:0000303|PubMed:2167437, ECO:0000303|PubMed:7520751"
FT                   /id="VSP_002958"
FT   VAR_SEQ         32..61
FT                   /note="QPWGAPVEVESFLVHPGDLLQLRCRLRDDV -> CPDLQEAKSCSASFHSIT
FT                   PLPFGLGTRLSD (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:1846977"
FT                   /id="VSP_009836"
FT   VAR_SEQ         62..822
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:1846977"
FT                   /id="VSP_009837"
FT   VAR_SEQ         119
FT                   /note="S -> SVPI (in isoform 19)"
FT                   /evidence="ECO:0000303|PubMed:1652059,
FT                   ECO:0000303|PubMed:20139426"
FT                   /id="VSP_038470"
FT   VAR_SEQ         120..150
FT                   /note="DALPSSEDDDDDDDSSSEEKETDNTKPNRMP -> ACPDLQEAKWCSASFHS
FT                   ITPLPFGLGTRLSD (in isoform 16)"
FT                   /evidence="ECO:0000303|PubMed:1650441"
FT                   /id="VSP_009838"
FT   VAR_SEQ         148..149
FT                   /note="Missing (in isoform 14, isoform 15, isoform 18,
FT                   isoform 19 and isoform 21)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:1650441,
FT                   ECO:0000303|PubMed:1652059, ECO:0000303|PubMed:1662973,
FT                   ECO:0000303|PubMed:1722683, ECO:0000303|PubMed:20139426,
FT                   ECO:0000303|PubMed:2162671, ECO:0000303|PubMed:2167437,
FT                   ECO:0000303|PubMed:7520751, ECO:0000303|Ref.12"
FT                   /id="VSP_002959"
FT   VAR_SEQ         151..822
FT                   /note="Missing (in isoform 16)"
FT                   /evidence="ECO:0000303|PubMed:1650441"
FT                   /id="VSP_009839"
FT   VAR_SEQ         313..391
FT                   /note="TAGVNTTDKEMEVLHLRNVSFEDAGEYTCLAGNSIGLSHHSAWLTVLEALEE
FT                   RPAVMTSPLYLEIIIYCTGAFLISCMV -> VIMAPVFVGQSTGKETTVSGAQVPVGRL
FT                   SCPRMGSFLTLQAHTLHLSRDLATSPRTSNRGHKVEVSWEQRAAGMGGAGL (in
FT                   isoform 17 and isoform 18)"
FT                   /evidence="ECO:0000303|PubMed:2167437"
FT                   /id="VSP_009840"
FT   VAR_SEQ         313..360
FT                   /note="TAGVNTTDKEMEVLHLRNVSFEDAGEYTCLAGNSIGLSHHSAWLTVLE ->
FT                   HSGINSSDAEVLTLFNVTEAQSGEYVCKVSNYIGEANQSAWLTVTRP (in isoform
FT                   19)"
FT                   /evidence="ECO:0000303|PubMed:1652059,
FT                   ECO:0000303|PubMed:20139426"
FT                   /id="VSP_038471"
FT   VAR_SEQ         392..822
FT                   /note="Missing (in isoform 17 and isoform 18)"
FT                   /evidence="ECO:0000303|PubMed:2167437"
FT                   /id="VSP_009841"
FT   VAR_SEQ         427..428
FT                   /note="Missing (in isoform 20)"
FT                   /evidence="ECO:0000303|Ref.12"
FT                   /id="VSP_041918"
FT   VAR_SEQ         428..429
FT                   /note="Missing (in isoform 4, isoform 5, isoform 8, isoform
FT                   9, isoform 12 and isoform 13)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:1846977"
FT                   /id="VSP_002960"
FT   VAR_SEQ         619..662
FT                   /note="CIHRDLAARNVLVTEDNVMKIADFGLARDIHHIDYYKKTTNGRL -> VWNL
FT                   KAPLVHTPRPGSQECPGDRGQCDEDSRLWPRTGHSPHRLL (in isoform 2,
FT                   isoform 5, isoform 7, isoform 9, isoform 11 and isoform
FT                   13)"
FT                   /evidence="ECO:0000303|PubMed:1846977"
FT                   /id="VSP_009842"
FT   VAR_SEQ         663..822
FT                   /note="Missing (in isoform 2, isoform 5, isoform 7, isoform
FT                   9, isoform 11 and isoform 13)"
FT                   /evidence="ECO:0000303|PubMed:1846977"
FT                   /id="VSP_009843"
FT   VARIANT         4
FT                   /note="W -> C (in HH2; unknown pathological significance;
FT                   dbSNP:rs760884357)"
FT                   /evidence="ECO:0000269|PubMed:26277103"
FT                   /id="VAR_074012"
FT   VARIANT         22
FT                   /note="R -> S (in dbSNP:rs17175750)"
FT                   /evidence="ECO:0000269|Ref.13"
FT                   /id="VAR_019290"
FT   VARIANT         48
FT                   /note="G -> S (in HH2; phenotype consistent with normosmic
FT                   idiopathic hypogonadotropic hypogonadism;
FT                   dbSNP:rs121909640)"
FT                   /evidence="ECO:0000269|PubMed:16882753"
FT                   /id="VAR_030968"
FT   VARIANT         70
FT                   /note="G -> R (in HH2; dbSNP:rs140254426)"
FT                   /evidence="ECO:0000269|PubMed:25077900"
FT                   /id="VAR_072993"
FT   VARIANT         77
FT                   /note="N -> K (in dbSNP:rs767195580)"
FT                   /evidence="ECO:0000269|PubMed:17154279"
FT                   /id="VAR_030969"
FT   VARIANT         78
FT                   /note="R -> C (in HH2; dbSNP:rs1554570706)"
FT                   /evidence="ECO:0000269|PubMed:16764984"
FT                   /id="VAR_030970"
FT   VARIANT         96
FT                   /note="S -> C (in HH2; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:26277103"
FT                   /id="VAR_074013"
FT   VARIANT         97
FT                   /note="G -> D (in HH2)"
FT                   /evidence="ECO:0000269|PubMed:12627230"
FT                   /id="VAR_017885"
FT   VARIANT         99
FT                   /note="Y -> C (in HH2; impairs the tertiary folding
FT                   resulting in incomplete glycosylation and reduced cell
FT                   surface expression; dbSNP:rs727505373)"
FT                   /evidence="ECO:0000269|PubMed:12627230,
FT                   ECO:0000269|PubMed:19820032"
FT                   /id="VAR_017886"
FT   VARIANT         101
FT                   /note="C -> F (in HH2)"
FT                   /evidence="ECO:0000269|PubMed:17154279"
FT                   /id="VAR_030971"
FT   VARIANT         102
FT                   /note="V -> I (in HH2; dbSNP:rs55642501)"
FT                   /evidence="ECO:0000269|PubMed:15605412,
FT                   ECO:0000269|PubMed:16764984"
FT                   /id="VAR_030972"
FT   VARIANT         116
FT                   /note="V -> I (in HH2; dbSNP:rs747842199)"
FT                   /evidence="ECO:0000269|PubMed:25077900"
FT                   /id="VAR_072994"
FT   VARIANT         117
FT                   /note="N -> S (in HH2; some patients also carry GNRHR
FT                   mutations; dbSNP:rs780765366)"
FT                   /evidence="ECO:0000269|PubMed:19820032,
FT                   ECO:0000269|PubMed:23643382"
FT                   /id="VAR_069288"
FT   VARIANT         125
FT                   /note="S -> L (in a breast infiltrating ductal carcinoma
FT                   sample; somatic mutation; dbSNP:rs121913473)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042201"
FT   VARIANT         129
FT                   /note="D -> A (in HH2; dbSNP:rs765615419)"
FT                   /evidence="ECO:0000269|PubMed:15605412"
FT                   /id="VAR_030973"
FT   VARIANT         165
FT                   /note="L -> S (in HRTFDS; dbSNP:rs397515481)"
FT                   /evidence="ECO:0000269|PubMed:23812909"
FT                   /id="VAR_070851"
FT   VARIANT         167
FT                   /note="A -> S (in HH2; with cleft palate, corpus callosum
FT                   agenesis, unilateral deafness and fusion of fourth and
FT                   fifth metacarpal bones; dbSNP:rs121909630)"
FT                   /evidence="ECO:0000269|PubMed:12627230"
FT                   /id="VAR_017887"
FT   VARIANT         174
FT                   /note="V -> A (in HH2)"
FT                   /evidence="ECO:0000269|PubMed:25077900"
FT                   /id="VAR_072995"
FT   VARIANT         178
FT                   /note="C -> S (in HH2; with severe ear anomalies)"
FT                   /evidence="ECO:0000269|PubMed:16757108"
FT                   /id="VAR_030974"
FT   VARIANT         191
FT                   /note="L -> S (in HRTFDS; dbSNP:rs869025669)"
FT                   /evidence="ECO:0000269|PubMed:23812909"
FT                   /id="VAR_070852"
FT   VARIANT         213
FT                   /note="W -> G (in dbSNP:rs17851623)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_030975"
FT   VARIANT         224
FT                   /note="D -> H (in HH2)"
FT                   /evidence="ECO:0000269|PubMed:16764984"
FT                   /id="VAR_030976"
FT   VARIANT         228
FT                   /note="Y -> D (in HH2; some patients also carry KISS1R
FT                   mutations; impairs the tertiary folding resulting in
FT                   incomplete glycosylation and reduced cell surface
FT                   expression)"
FT                   /evidence="ECO:0000269|PubMed:19820032,
FT                   ECO:0000269|PubMed:23643382"
FT                   /id="VAR_069289"
FT   VARIANT         237
FT                   /note="G -> D (in HH2)"
FT                   /evidence="ECO:0000269|PubMed:16764984"
FT                   /id="VAR_030977"
FT   VARIANT         237
FT                   /note="G -> S (in HH2; with or without anosmia; also found
FT                   in a family member with isolated anosmia; may impair proper
FT                   folding; dbSNP:rs121909635)"
FT                   /evidence="ECO:0000269|PubMed:16606836"
FT                   /id="VAR_030978"
FT   VARIANT         239
FT                   /note="I -> T (in HH2; some patients also carry PROKR2 and
FT                   GNRH1 mutations; impairs the tertiary folding resulting in
FT                   incomplete glycosylation and reduced cell surface
FT                   expression)"
FT                   /evidence="ECO:0000269|PubMed:19820032,
FT                   ECO:0000269|PubMed:23643382"
FT                   /id="VAR_069290"
FT   VARIANT         245
FT                   /note="L -> P (in HH2)"
FT                   /evidence="ECO:0000269|PubMed:16882753"
FT                   /id="VAR_030979"
FT   VARIANT         250
FT                   /note="R -> Q (in HH2; with or without anosmia; results in
FT                   Kallmann syndrome in the presence of HS6ST1 mutation TRP-
FT                   306; reduces receptor affinity for fibroblast growth
FT                   factor; dbSNP:rs121909645)"
FT                   /evidence="ECO:0000269|PubMed:19820032,
FT                   ECO:0000269|PubMed:21700882, ECO:0000269|PubMed:23643382,
FT                   ECO:0000269|PubMed:25077900"
FT                   /id="VAR_069291"
FT   VARIANT         250
FT                   /note="R -> W (in HH2)"
FT                   /evidence="ECO:0000269|PubMed:16882753,
FT                   ECO:0000269|PubMed:17154279"
FT                   /id="VAR_030980"
FT   VARIANT         252
FT                   /note="P -> R (in PS and JWS; dbSNP:rs121909627)"
FT                   /evidence="ECO:0000269|PubMed:10861678,
FT                   ECO:0000269|PubMed:7874169"
FT                   /id="VAR_004111"
FT   VARIANT         252
FT                   /note="P -> T (in a lung bronchoalveolar carcinoma sample;
FT                   somatic mutation; dbSNP:rs121913472)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042202"
FT   VARIANT         254
FT                   /note="R -> Q (in HH2)"
FT                   /evidence="ECO:0000269|PubMed:16764984"
FT                   /id="VAR_030981"
FT   VARIANT         270
FT                   /note="G -> D (in HH2)"
FT                   /evidence="ECO:0000269|PubMed:17154279"
FT                   /id="VAR_030982"
FT   VARIANT         273
FT                   /note="V -> M (in HH2; dbSNP:rs1131691929)"
FT                   /evidence="ECO:0000269|PubMed:15605412,
FT                   ECO:0000269|PubMed:16764984"
FT                   /id="VAR_030983"
FT   VARIANT         274
FT                   /note="E -> G (in HH2; also found in a family member with
FT                   isolated anosmia; dbSNP:rs727505369)"
FT                   /id="VAR_030984"
FT   VARIANT         277
FT                   /note="C -> Y (in HH2)"
FT                   /evidence="ECO:0000269|PubMed:12627230"
FT                   /id="VAR_017888"
FT   VARIANT         283
FT                   /note="P -> R (in HH2)"
FT                   /evidence="ECO:0000269|PubMed:17154279"
FT                   /id="VAR_030985"
FT   VARIANT         300
FT                   /note="I -> T (in TRIGNO1; dbSNP:rs121909633)"
FT                   /evidence="ECO:0000269|PubMed:11173846"
FT                   /id="VAR_030986"
FT   VARIANT         324..822
FT                   /note="Missing (in HH2)"
FT                   /evidence="ECO:0000269|PubMed:17154279"
FT                   /id="VAR_080328"
FT   VARIANT         330
FT                   /note="N -> I (in OGD; dbSNP:rs121909632)"
FT                   /evidence="ECO:0000269|PubMed:15625620,
FT                   ECO:0000269|PubMed:16470795"
FT                   /id="VAR_030987"
FT   VARIANT         332
FT                   /note="S -> C (in HH2)"
FT                   /evidence="ECO:0000269|PubMed:17154279"
FT                   /id="VAR_030988"
FT   VARIANT         339
FT                   /note="Y -> C (in HH2)"
FT                   /evidence="ECO:0000269|PubMed:16764984"
FT                   /id="VAR_030989"
FT   VARIANT         342
FT                   /note="L -> S (in HH2; phenotype consistent with Kallmann
FT                   syndrome; the patient also carries a splice site mutation
FT                   in NSMF; dbSNP:rs121909638)"
FT                   /evidence="ECO:0000269|PubMed:23643382"
FT                   /id="VAR_069954"
FT   VARIANT         343
FT                   /note="A -> V (in HH2)"
FT                   /evidence="ECO:0000269|PubMed:16882753"
FT                   /id="VAR_030990"
FT   VARIANT         346
FT                   /note="S -> C (in HH2; also found in a family member with
FT                   isolated anosmia)"
FT                   /evidence="ECO:0000269|PubMed:16764984"
FT                   /id="VAR_030991"
FT   VARIANT         348
FT                   /note="G -> R (in HH2; phenotype consistent with Kallmann
FT                   syndrome; the patient also carries a mutation in IL17RD;
FT                   dbSNP:rs886037634)"
FT                   /evidence="ECO:0000269|PubMed:23643382,
FT                   ECO:0000269|PubMed:25077900"
FT                   /id="VAR_069955"
FT   VARIANT         366
FT                   /note="P -> L (in HH2; with or without anosmia;
FT                   dbSNP:rs121909641)"
FT                   /evidence="ECO:0000269|PubMed:16882753"
FT                   /id="VAR_030992"
FT   VARIANT         374
FT                   /note="Y -> C (in OGD; elevated basal activity and
FT                   increased FGF2-mediated activity; dbSNP:rs121909631)"
FT                   /evidence="ECO:0000269|PubMed:15625620"
FT                   /id="VAR_030993"
FT   VARIANT         381
FT                   /note="C -> R (in OGD; dbSNP:rs121909634)"
FT                   /evidence="ECO:0000269|PubMed:15625620,
FT                   ECO:0000269|PubMed:16470795"
FT                   /id="VAR_030994"
FT   VARIANT         470
FT                   /note="R -> L (in HH2; some patients also carry GNRHR
FT                   mutations; dbSNP:rs121909637)"
FT                   /evidence="ECO:0000269|PubMed:19820032,
FT                   ECO:0000269|PubMed:23643382"
FT                   /id="VAR_069292"
FT   VARIANT         483
FT                   /note="P -> T (in HH2; phenotype consistent with Kallmann
FT                   syndrome; the patient also carries a rare variant in SPRY4;
FT                   dbSNP:rs397515444)"
FT                   /evidence="ECO:0000269|PubMed:23643382"
FT                   /id="VAR_069956"
FT   VARIANT         490
FT                   /note="G -> R (in HRTFDS; dbSNP:rs869025670)"
FT                   /evidence="ECO:0000269|PubMed:23812909"
FT                   /id="VAR_070853"
FT   VARIANT         520
FT                   /note="A -> T (in HH2; dbSNP:rs749758370)"
FT                   /evidence="ECO:0000269|PubMed:15605412"
FT                   /id="VAR_030995"
FT   VARIANT         538
FT                   /note="I -> V (in HH2)"
FT                   /evidence="ECO:0000269|PubMed:16764984"
FT                   /id="VAR_030996"
FT   VARIANT         546
FT                   /note="N -> K (in ECCL; somatic mutation; activating
FT                   mutation; strongly increased speed of the first
FT                   autophosphorylation and loss of the normal sequential order
FT                   of autophosphorylation; dbSNP:rs779707422)"
FT                   /evidence="ECO:0000269|PubMed:19224897,
FT                   ECO:0000269|PubMed:26942290"
FT                   /id="VAR_075853"
FT   VARIANT         561
FT                   /note="V -> M"
FT                   /evidence="ECO:0000269|PubMed:26942290"
FT                   /id="VAR_075854"
FT   VARIANT         607
FT                   /note="V -> M (in HH2; with bimanual synkinesis;
FT                   dbSNP:rs121909629)"
FT                   /evidence="ECO:0000269|PubMed:12627230"
FT                   /id="VAR_017889"
FT   VARIANT         618
FT                   /note="K -> N (in HH2; some patients also carry GNRHR
FT                   mutations; impairs tyrosine kinase activity)"
FT                   /evidence="ECO:0000269|PubMed:19820032,
FT                   ECO:0000269|PubMed:23643382"
FT                   /id="VAR_069293"
FT   VARIANT         621
FT                   /note="H -> R (in HH2)"
FT                   /evidence="ECO:0000269|PubMed:17154279"
FT                   /id="VAR_030997"
FT   VARIANT         622..822
FT                   /note="Missing (in HH2)"
FT                   /evidence="ECO:0000269|PubMed:12627230"
FT                   /id="VAR_080329"
FT   VARIANT         622
FT                   /note="R -> G (in HH2; with severe ear anomalies;
FT                   dbSNP:rs121909628)"
FT                   /evidence="ECO:0000269|PubMed:16757108"
FT                   /id="VAR_030998"
FT   VARIANT         622
FT                   /note="R -> Q (in HH2)"
FT                   /evidence="ECO:0000269|PubMed:16757108"
FT                   /id="VAR_030999"
FT   VARIANT         623
FT                   /note="D -> Y (in HRTFDS; dbSNP:rs398122946)"
FT                   /evidence="ECO:0000269|PubMed:23812909"
FT                   /id="VAR_070854"
FT   VARIANT         627
FT                   /note="R -> T (in HRTFDS; dbSNP:rs869025671)"
FT                   /evidence="ECO:0000269|PubMed:24888332"
FT                   /id="VAR_071460"
FT   VARIANT         628
FT                   /note="N -> K (in HRTFDS; dbSNP:rs869025672)"
FT                   /evidence="ECO:0000269|PubMed:23812909"
FT                   /id="VAR_070855"
FT   VARIANT         656
FT                   /note="K -> E (in ECCL; somatic mutation;
FT                   dbSNP:rs869320694)"
FT                   /evidence="ECO:0000269|PubMed:26942290"
FT                   /id="VAR_075855"
FT   VARIANT         661..822
FT                   /note="Missing (in HH2)"
FT                   /evidence="ECO:0000269|PubMed:17154279"
FT                   /id="VAR_080330"
FT   VARIANT         664
FT                   /note="V -> L (in a lung large cell carcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042203"
FT   VARIANT         666
FT                   /note="W -> R (in HH2; with cleft palate;
FT                   dbSNP:rs1563433902)"
FT                   /evidence="ECO:0000269|PubMed:12627230"
FT                   /id="VAR_017890"
FT   VARIANT         670
FT                   /note="E -> K (in HH2; phenotype consistent with Kallmann
FT                   syndrome; the patient also carries a rare variant in FLRT3;
FT                   dbSNP:rs397515446)"
FT                   /evidence="ECO:0000269|PubMed:23643382"
FT                   /id="VAR_069957"
FT   VARIANT         671
FT                   /note="A -> P (in HH2)"
FT                   /evidence="ECO:0000269|PubMed:19820032"
FT                   /id="VAR_069294"
FT   VARIANT         685
FT                   /note="S -> F (in HH2)"
FT                   /evidence="ECO:0000269|PubMed:17154279"
FT                   /id="VAR_031000"
FT   VARIANT         687
FT                   /note="G -> R (in HH2; dbSNP:rs727505376)"
FT                   /evidence="ECO:0000269|PubMed:15845591,
FT                   ECO:0000269|PubMed:22927827"
FT                   /id="VAR_031001"
FT   VARIANT         692
FT                   /note="E -> G (in HH2; phenotype consistent with Kallmann
FT                   syndrome; the patient also carries a rare variant in DUSP6;
FT                   dbSNP:rs397515445)"
FT                   /evidence="ECO:0000269|PubMed:23643382"
FT                   /id="VAR_069958"
FT   VARIANT         693
FT                   /note="I -> F (in HH2)"
FT                   /evidence="ECO:0000269|PubMed:17154279"
FT                   /id="VAR_031002"
FT   VARIANT         703
FT                   /note="G -> R (in HH2)"
FT                   /evidence="ECO:0000269|PubMed:16764984"
FT                   /id="VAR_031003"
FT   VARIANT         703
FT                   /note="G -> S (in HH2; dbSNP:rs768957161)"
FT                   /evidence="ECO:0000269|PubMed:16764984"
FT                   /id="VAR_031004"
FT   VARIANT         719
FT                   /note="M -> R (in HH2)"
FT                   /evidence="ECO:0000269|PubMed:12627230"
FT                   /id="VAR_017891"
FT   VARIANT         719
FT                   /note="M -> V (in HH2; unknown pathological significance;
FT                   dbSNP:rs1085307879)"
FT                   /evidence="ECO:0000269|PubMed:26277103"
FT                   /id="VAR_074014"
FT   VARIANT         722
FT                   /note="P -> H (in HH2; associated with K-724; also found in
FT                   a family member with isolated anosmia; reduced tyrosine
FT                   kinase activity; dbSNP:rs267606805)"
FT                   /evidence="ECO:0000269|PubMed:16606836,
FT                   ECO:0000269|PubMed:23643382"
FT                   /id="VAR_031005"
FT   VARIANT         722
FT                   /note="P -> S (in HH2; dbSNP:rs121909642)"
FT                   /evidence="ECO:0000269|PubMed:16882753"
FT                   /id="VAR_031006"
FT   VARIANT         724
FT                   /note="N -> K (in HH2; associated with H-722; also found in
FT                   a family member with isolated anosmia; reduced tyrosine
FT                   kinase activity; dbSNP:rs267606806)"
FT                   /evidence="ECO:0000269|PubMed:16606836,
FT                   ECO:0000269|PubMed:23643382"
FT                   /id="VAR_031007"
FT   VARIANT         725
FT                   /note="C -> Y (in HRTFDS; dbSNP:rs398122945)"
FT                   /evidence="ECO:0000269|PubMed:23812909"
FT                   /id="VAR_070856"
FT   VARIANT         745
FT                   /note="P -> S (in HH2)"
FT                   /evidence="ECO:0000269|PubMed:15001591,
FT                   ECO:0000269|PubMed:15845591"
FT                   /id="VAR_031008"
FT   VARIANT         768
FT                   /note="D -> Y (in HH2; the patient also carries a rare
FT                   variant in FGF8; dbSNP:rs121909644)"
FT                   /evidence="ECO:0000269|PubMed:23643382"
FT                   /id="VAR_069959"
FT   VARIANT         769
FT                   /note="L -> V (in dbSNP:rs2956723)"
FT                   /evidence="ECO:0000269|PubMed:16764984"
FT                   /id="VAR_031009"
FT   VARIANT         772
FT                   /note="P -> S (in dbSNP:rs56234888)"
FT                   /evidence="ECO:0000269|PubMed:12627230,
FT                   ECO:0000269|PubMed:17154279"
FT                   /id="VAR_017892"
FT   VARIANT         795
FT                   /note="V -> I (in HH2; also found in a family member with
FT                   isolated anosmia; dbSNP:rs781328162)"
FT                   /evidence="ECO:0000269|PubMed:16882753"
FT                   /id="VAR_031010"
FT   VARIANT         818
FT                   /note="G -> R (in dbSNP:rs17182456)"
FT                   /evidence="ECO:0000269|Ref.13"
FT                   /id="VAR_019291"
FT   VARIANT         822
FT                   /note="R -> C (in dbSNP:rs17182463)"
FT                   /evidence="ECO:0000269|PubMed:17154279, ECO:0000269|Ref.13"
FT                   /id="VAR_019292"
FT   MUTAGEN         514
FT                   /note="K->A: Loss of kinase activity."
FT                   /evidence="ECO:0000269|PubMed:15117958"
FT   MUTAGEN         577
FT                   /note="R->E: Strongly reduced autophosphorylation in
FT                   response to FGF signaling. No effect on in vitro kinase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:20133753"
FT   MUTAGEN         609
FT                   /note="R->V: Abolishes interaction with PLCG1."
FT   MUTAGEN         623
FT                   /note="D->A: Loss of kinase activity."
FT                   /evidence="ECO:0000269|PubMed:19224897"
FT   MUTAGEN         653
FT                   /note="Y->F: No effect on kinase activity. Loss of
FT                   autophosphorylation and kinase activity; when associated
FT                   with F-654."
FT                   /evidence="ECO:0000269|PubMed:8622701"
FT   MUTAGEN         654
FT                   /note="Y->F: Reduced kinase activity. Loss of
FT                   autophosphorylation and kinase activity; when associated
FT                   with F-653."
FT                   /evidence="ECO:0000269|PubMed:8622701"
FT   MUTAGEN         755
FT                   /note="D->V: Abolishes interaction with PLCG1."
FT   MUTAGEN         766
FT                   /note="Y->F: Abolishes interaction with PLCG1 and SHB.
FT                   Decreases phosphorylation of FRS2, activation of RAS and
FT                   MAP kinase signaling and stimulation of cell
FT                   proliferation."
FT                   /evidence="ECO:0000269|PubMed:12181353,
FT                   ECO:0000269|PubMed:1379697, ECO:0000269|PubMed:1379698,
FT                   ECO:0000269|PubMed:7516330"
FT   CONFLICT        24
FT                   /note="S -> C (in Ref. 8; AAA35958/AAA35959)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        192
FT                   /note="K -> E (in Ref. 3; AAA35837)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        194
FT                   /note="G -> S (in Ref. 5; AAA35835)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        196
FT                   /note="E -> G (in Ref. 16; no nucleotide entry)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        223
FT                   /note="S -> F (in Ref. 12; BAD96438)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        308
FT                   /note="V -> A (in Ref. 8; AAA35958/AAA35959)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        364
FT                   /note="E -> Q (in Ref. 18; CAA68679)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        469
FT                   /note="P -> L (in Ref. 1; AAA75007)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        482
FT                   /note="K -> R (in Ref. 12; BAD96438)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        576
FT                   /note="R -> W (in Ref. 12; BAD96438)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        817
FT                   /note="G -> R (in Ref. 4; CAA36101)"
FT                   /evidence="ECO:0000305"
FT   STRAND          40..42
FT                   /evidence="ECO:0007829|PDB:2CR3"
FT   STRAND          51..54
FT                   /evidence="ECO:0007829|PDB:2CR3"
FT   STRAND          63..72
FT                   /evidence="ECO:0007829|PDB:2CR3"
FT   STRAND          77..81
FT                   /evidence="ECO:0007829|PDB:2CR3"
FT   STRAND          83..88
FT                   /evidence="ECO:0007829|PDB:2CR3"
FT   TURN            93..95
FT                   /evidence="ECO:0007829|PDB:2CR3"
FT   STRAND          97..105
FT                   /evidence="ECO:0007829|PDB:2CR3"
FT   STRAND          108..116
FT                   /evidence="ECO:0007829|PDB:2CR3"
FT   STRAND          151..156
FT                   /evidence="ECO:0007829|PDB:5W59"
FT   HELIX           159..161
FT                   /evidence="ECO:0007829|PDB:5W59"
FT   STRAND          165..169
FT                   /evidence="ECO:0007829|PDB:5W59"
FT   STRAND          174..177
FT                   /evidence="ECO:0007829|PDB:5W59"
FT   STRAND          180..184
FT                   /evidence="ECO:0007829|PDB:5W59"
FT   STRAND          187..192
FT                   /evidence="ECO:0007829|PDB:5W59"
FT   HELIX           199..201
FT                   /evidence="ECO:0007829|PDB:5W59"
FT   STRAND          207..209
FT                   /evidence="ECO:0007829|PDB:5W59"
FT   TURN            210..213
FT                   /evidence="ECO:0007829|PDB:5W59"
FT   STRAND          214..217
FT                   /evidence="ECO:0007829|PDB:5W59"
FT   HELIX           222..224
FT                   /evidence="ECO:0007829|PDB:5W59"
FT   STRAND          226..234
FT                   /evidence="ECO:0007829|PDB:5W59"
FT   STRAND          237..248
FT                   /evidence="ECO:0007829|PDB:5W59"
FT   STRAND          265..268
FT                   /evidence="ECO:0007829|PDB:5W59"
FT   STRAND          269..271
FT                   /evidence="ECO:0007829|PDB:5W21"
FT   STRAND          273..276
FT                   /evidence="ECO:0007829|PDB:5W59"
FT   STRAND          286..293
FT                   /evidence="ECO:0007829|PDB:5W59"
FT   STRAND          295..297
FT                   /evidence="ECO:0007829|PDB:1CVS"
FT   STRAND          307..313
FT                   /evidence="ECO:0007829|PDB:5W59"
FT   HELIX           320..323
FT                   /evidence="ECO:0007829|PDB:5W59"
FT   STRAND          325..328
FT                   /evidence="ECO:0007829|PDB:5W59"
FT   HELIX           333..335
FT                   /evidence="ECO:0007829|PDB:1CVS"
FT   STRAND          337..345
FT                   /evidence="ECO:0007829|PDB:5W59"
FT   STRAND          348..359
FT                   /evidence="ECO:0007829|PDB:5W59"
FT   TURN            461..463
FT                   /evidence="ECO:0007829|PDB:5O49"
FT   TURN            469..471
FT                   /evidence="ECO:0007829|PDB:5EW8"
FT   HELIX           475..477
FT                   /evidence="ECO:0007829|PDB:5EW8"
FT   STRAND          478..486
FT                   /evidence="ECO:0007829|PDB:5EW8"
FT   STRAND          488..499
FT                   /evidence="ECO:0007829|PDB:5EW8"
FT   STRAND          501..503
FT                   /evidence="ECO:0007829|PDB:5EW8"
FT   STRAND          508..516
FT                   /evidence="ECO:0007829|PDB:5EW8"
FT   HELIX           522..538
FT                   /evidence="ECO:0007829|PDB:5EW8"
FT   STRAND          547..551
FT                   /evidence="ECO:0007829|PDB:5EW8"
FT   STRAND          553..555
FT                   /evidence="ECO:0007829|PDB:5EW8"
FT   STRAND          558..562
FT                   /evidence="ECO:0007829|PDB:5EW8"
FT   HELIX           569..574
FT                   /evidence="ECO:0007829|PDB:5EW8"
FT   STRAND          582..584
FT                   /evidence="ECO:0007829|PDB:6MZQ"
FT   STRAND          585..588
FT                   /evidence="ECO:0007829|PDB:3KXX"
FT   HELIX           591..593
FT                   /evidence="ECO:0007829|PDB:3KXX"
FT   HELIX           597..616
FT                   /evidence="ECO:0007829|PDB:5EW8"
FT   HELIX           626..628
FT                   /evidence="ECO:0007829|PDB:5EW8"
FT   STRAND          629..631
FT                   /evidence="ECO:0007829|PDB:5EW8"
FT   STRAND          637..639
FT                   /evidence="ECO:0007829|PDB:5EW8"
FT   STRAND          641..643
FT                   /evidence="ECO:0007829|PDB:3JS2"
FT   HELIX           648..650
FT                   /evidence="ECO:0007829|PDB:5EW8"
FT   STRAND          653..655
FT                   /evidence="ECO:0007829|PDB:4UWY"
FT   STRAND          658..660
FT                   /evidence="ECO:0007829|PDB:5AM7"
FT   HELIX           663..666
FT                   /evidence="ECO:0007829|PDB:5EW8"
FT   HELIX           669..674
FT                   /evidence="ECO:0007829|PDB:5EW8"
FT   STRAND          676..678
FT                   /evidence="ECO:0007829|PDB:3GQI"
FT   HELIX           679..694
FT                   /evidence="ECO:0007829|PDB:5EW8"
FT   HELIX           706..714
FT                   /evidence="ECO:0007829|PDB:5EW8"
FT   STRAND          722..724
FT                   /evidence="ECO:0007829|PDB:4RWL"
FT   HELIX           727..736
FT                   /evidence="ECO:0007829|PDB:5EW8"
FT   HELIX           741..743
FT                   /evidence="ECO:0007829|PDB:5EW8"
FT   HELIX           747..760
FT                   /evidence="ECO:0007829|PDB:5EW8"
FT   VARIANT         P11362-19:353
FT                   /note="A -> T (in HH2; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:26277103"
FT                   /id="VAR_082843"
SQ   SEQUENCE   822 AA;  91868 MW;  93A01B5D78C3E72C CRC64;
     MWSWKCLLFW AVLVTATLCT ARPSPTLPEQ AQPWGAPVEV ESFLVHPGDL LQLRCRLRDD
     VQSINWLRDG VQLAESNRTR ITGEEVEVQD SVPADSGLYA CVTSSPSGSD TTYFSVNVSD
     ALPSSEDDDD DDDSSSEEKE TDNTKPNRMP VAPYWTSPEK MEKKLHAVPA AKTVKFKCPS
     SGTPNPTLRW LKNGKEFKPD HRIGGYKVRY ATWSIIMDSV VPSDKGNYTC IVENEYGSIN
     HTYQLDVVER SPHRPILQAG LPANKTVALG SNVEFMCKVY SDPQPHIQWL KHIEVNGSKI
     GPDNLPYVQI LKTAGVNTTD KEMEVLHLRN VSFEDAGEYT CLAGNSIGLS HHSAWLTVLE
     ALEERPAVMT SPLYLEIIIY CTGAFLISCM VGSVIVYKMK SGTKKSDFHS QMAVHKLAKS
     IPLRRQVTVS ADSSASMNSG VLLVRPSRLS SSGTPMLAGV SEYELPEDPR WELPRDRLVL
     GKPLGEGCFG QVVLAEAIGL DKDKPNRVTK VAVKMLKSDA TEKDLSDLIS EMEMMKMIGK
     HKNIINLLGA CTQDGPLYVI VEYASKGNLR EYLQARRPPG LEYCYNPSHN PEEQLSSKDL
     VSCAYQVARG MEYLASKKCI HRDLAARNVL VTEDNVMKIA DFGLARDIHH IDYYKKTTNG
     RLPVKWMAPE ALFDRIYTHQ SDVWSFGVLL WEIFTLGGSP YPGVPVEELF KLLKEGHRMD
     KPSNCTNELY MMMRDCWHAV PSQRPTFKQL VEDLDRIVAL TSNQEYLDLS MPLDQYSPSF
     PDTRSSTCSS GEDSVFSHEP LPEEPCLPRH PAQLANGGLK RR
//